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CELL AND PROTEIN-BASED SENSING SYSTEMS FOR THE DETECTION OF 
ENVIRONMENTALLY AND PHYSIOLOGICALLY RELEVANT MOLECULES 
 
The detection of small molecules in complex sample matrices such as 
environmental (surface and ground water, sediment, etc.) and biological (blood, 
serum, plasma, etc.) samples is of paramount importance for monitoring the 
distribution of environmental pollutants and their patterns of exposure within the 
population as well as diagnosing and managing diseases.  Biosensors have 
demonstrated a singular ability to sensitively and selectively detect analytes in 
complex samples without the need for extensive sample preparation and pre-
treatment.  Nature has demonstrated myriad examples of exquisite selectivity in 
spite of complexity and we seek to take advantage of that attribute in the 
development of novel biosensing systems.   
 In the work presented here, we have developed both cell- and protein-
based biosensing systems for the detection of hydroxylated polychlorinated 
biphenyls (OH-PCBs) and protein-based sensing systems for the detection of 
glucose.   In the development of a whole-cell sensing system, the regulatory 
protein, HbpR, and its associated promoter was used to modulate the expression 
of luciferase.   Additionally, the effector binding domain of HbpR, HbpR-A, was 
isolated and modified with a solvatochromic fluorophore resulting in a protein-
based sensing system.  For the detection of glucose, two different glucose 
binding proteins were engineered in an effort to tailor their characteristics, such 
as binding affinity and thermal stability, to develop a rugged, sensitive protein-
based sensing system.  We envision that these biosensing systems will find 
applications in the areas of environmental pollutant monitoring and the 
management and treatment of diseases such as diabetes. 
 
KEYWORDS:  biosesnors, binding proteins, regulatory proteins, protein-based 
biosensors, cell-based biosensors 
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CHAPTER ONE 
 
INTRODUCTION 
Portions reprinted from Turner, et al.  Cell-Based Bioluminescent Biosensors 
in "Analytical Chemiluminescence and Bioluminescence: Past, Present and 
Future", A. Roda, Ed., Royal Society of Chemistry Press, Cambridge, United 
Kingdom, 2010 
 
A biosensor is defined as a device that employs biological components 
such as proteins, tissues, organelles, nucleic acids, or whole cells to detect a 
physicochemical change and produce a measurable signal.  Biosensors are 
typically composed of three parts:  the biological sensing element, the signal 
transducing element, electronic and signal processing components and a display 
unit.  The transducing element of a biosensor can produce a variety of signal 
outputs such as optical, piezoelectric, or electrochemical.  Biosensors can be 
categorized as either molecular-based (binding proteins, enzymes, antibodies, 
aptamers etc.) or cell-based (whole cells, tissues, organisms, etc.).  Biosensors 
can be designed with certain characteristics, which make them advantageous 
over traditional physicochemical analysis methods.  These characteristics include 
high specificity/selectivity, ease of use, and the ability to provide relevant data 
related to the bioavailability of the target analyte in a given sample.  Molecular-
based biosensors offer the advantage of having generally faster response times 
than cell-based ones, although they are typically less rugged due to the often 
fragile nature of many isolated biomolecules and they fail to provide information 
on the bioavailability of the compound of interest.[1]  Additionally, the production 
and isolation of biomolecules can be expensive and time-consuming.  In contrast, 
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cell-based biosensors are usually more tolerant of extreme conditions, although, 
in many cases, they can require longer analysis times.  Cell-based sensing 
systems also provide useful information on the bioavailability of the interrogated 
analyte and its ability to activate biochemical machinery, which can contribute to 
an increased understanding of the toxicity or physiological role of the compound 
of interest when this is, for example, an environmental pollutant or a biologically 
relevant molecule.  As a result of their respective desirable properties, both cell- 
and protein- based biosensing systems are finding increasing application in the 
fields of environmental and clinical analysis, drug discovery, and toxicology, and 
are becoming the focus of much research to improve their characteristics and 
engineer them to respond to a greater variety of stimuli and analytes present in 
the environment. 
 
DESIGN AND CONSTRUCTION OF BACTERIAL CELL-BASED 
BIOLUMINESCENT BIOSENSORS 
Bacterial cell-based biosensors share a common basic design and include 
similar components.  This basic design consists of an intact living cell containing 
a DNA sequence, in which the expression of a reporter gene/transducer is under 
the control of the promoter of a certain operon.  Within this basic design, there 
can be much variation depending on the cells being used as a host, the type of 
promoter that is utilized (either constitutive or inducible reporter expression), and 
the detection strategy that is being employed. 
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As cells grow and are metabolically active, biosensing systems that 
employ a constitutive promoter to regulate the expression of the reporter protein, 
often present a basal expression of reporter, which produces a measurable 
signal even in the absence of the target analyte.  This basal signal is reduced if 
the cells are subjected to stress as a result of exposure to toxic compounds or 
other adverse growing conditions.  Thus, this kind of cell-based biosensors that 
employ constitutive promoters to regulate the production of a reporter protein can 
effectively provide information on the overall toxicity of a sample under 
investigation.  However, it should be noted that such a system does not provide 
any information on the specific nature of the compounds that cause the toxicity to 
the cells or the sample. 
In contrast, the gene fusion of an inducible promoter to a reporter gene 
yields a cell-based biosensing system in which the expression of a reporter 
protein occurs only in the presence of a desired condition (Figures 1.1, 1.2).  
Therefore, the presence of an analyte of interest activates the expression of a 
reporter protein resulting in an increase of the signal produced by the reporter.  
An inducible cell-based sensing system such as this is preferred when the goal is 
to detect and quantify a particular compound or condition in the sample.  
Furthermore, combinations of these genetic operons using different reporter 
genes under the control of different promoters can be achieved within a single 
organism and yield a single cell-based biosensor capable of responding to 
multiple analytes, an advantage when developing multiplexed assays.[2, 3]  
Inducible promoters are typically regulated by transcriptional regulatory proteins, 
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Figure 1.1 Schematic of an operon/regulatory protein cell-based biosensor 
featuring a negatively regulated operon.  In the absence of the analyte, the 
regulatory protein is bound to the promoter on the reporter plasmid and prevents 
expression of the reporter protein.  As the analyte concentration increases, it 
binds the regulatory protein, and the analyte-regulatory protein complex 
dissociates from the reporter plasmid.  This triggers expression of the reporter 
protein, and a dose-dependent generation of the signal. 
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Figure 1.2 Schematic of an operon/regulatory protein cell-based biosensor 
featuring a positively regulated operon.  When an analyte is present, it binds 
to the regulatory protein.  This regulatory protein-analyte complex binds the 
promoter region on the reporter plasmid, thus triggering the expression of a 
reporter protein.  This produces a luminescent signal which is dependent on the 
concentration of the analyte. 
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a kind of protein that evolved as a response mechanism of an organism to stress.  
In general, when an extracellular stimulus/compound acts upon the organism, 
these proteins are able to specifically or selectively recognize and bind to this 
compound, and subsequently respond by triggering the production of other 
proteins involved in defense mechanisms.  These include the production of 
protein pumps that control the cellular efflux of the toxic compound(s), metabolic 
and synthetic pathway enzymes that degrade them, proteins that can sequester 
them, receptor proteins, etc.[1]  These inducible-promoter regulatory circuits are 
advantageous to the host organism in that they ensure that transcription of their 
gene products occurs only when required to increase their survival.  In the 
absence of an external stimulus, the regulatory circuit is turned off, no proteins 
are expressed from the genes, and the organism can conserve its resources and 
energy for other purposes.   
In cell-based biosensing systems, recombinant DNA methods are 
employed to replace the gene products of the native operon with a reporter gene 
that produces a desired signal in response to the presence of a specific 
compound recognized by the regulatory protein.  Thus, these systems combine 
the biospecific recognition afforded by the regulatory proteins with the signal 
generation stemming from the reporter gene.  An example of the design of one 
such system is shown in Figure 1.3 featuring the hbp operon from Pseudomonas 
azelaica.  The genes hbpC, hbpA, and hbpD of this operon are under the control 
of an operator/promoter that is regulated by the product of the gene, hbpR.   
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The enzymes, HbpC, HbpA, and HbpD are responsible for the degradation of 2-
hydroxybiphenyl.  A bacterial cell-based biosensor was constructed by replacing 
these structural genes with the reporter gene luxAB.  Further study of this 
construct demonstrated that it responded to a variety of hydroxylated 
polychlorinated biphenyls (OH-PCBs) resulting in an increase in bioluminescence 
in a dose-dependent manner.[4] 
 
REGULATION OF REPORTER GENE EXPRESSION 
Within the realm of inducible cell-based biosensing systems, the reporter 
gene expression may be positively or negatively regulated.  In a negatively 
regulated operon (Figure 1.1), a regulatory protein binds to an operator DNA 
sequence and prevents the expression of the reporter protein, with this binding 
being dependent on the presence or absence of the effector/analyte.  In one 
instance, the regulatory protein is initially bound to the operator region, thus 
repressing the expression of the reporter.  As the effector is added, it binds to the 
regulatory protein causing it to dissociate from the operator DNA sequence.  This 
results in an increased expression of the reporter protein.  The alternative is that 
the effector is required for binding of the regulatory protein to the operator.  In 
this case, as the effector is added, a regulatory protein-effector complex forms, 
which binds to the operator resulting in a decrease in reporter protein expression. 
Alternatively, in a positively regulated system (Figure 1.2) the operon 
regulation is mediated by a DNA sequence that acts as an “enhancer” of the 
system.  There are two different mechanisms by which this regulation occurs: In 
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the first possible mechanism, the regulatory protein is bound to the enhancer, 
and consequently, produces a high level of initial expression of the reporter 
protein.  As the concentration of the effector increases, it binds to the regulatory 
protein, causing its dissociation from the enhancer and, thus, reducing 
expression of the reporter gene.  In the second case, the effector is required for 
the binding of the regulatory protein to the enhancer sequence.  An increase in 
the effector concentration leads to the formation of a regulatory protein-effector 
complex which, in turn, binds to the enhancer DNA sequence and increases 
reporter protein expression. 
From an analytical standpoint, it is desirable to have the lowest possible 
initial signal and an increasing dose-dependent response as the concentration of 
the analyte of interest increases.  Thus, the most useful regulatory proteins are 
those from very tightly negatively regulated operons where the regulatory protein 
is initially bound to the operator and represses reporter protein synthesis.  
Accordingly, cell-based biosensing systems based upon these strategies, in 
general, afford the lowest limits of detection. 
 
REPORTER GENES AND THEIR ATTRIBUTES 
While the sensing element of a cell-based biosensing system determines 
the selectivity of its response, the reporter gene largely determines the sensitivity 
of the system.  In that regard, the variety of reporter genes available is steadily 
increasing and each of these reporter genes possesses unique attributes that 
must be considered in the design of a biosensing system.  The reporter gene of a 
10 
 
cell-based sensing system can yield a reporter protein that can generate a 
variety of different measurable signals.  This chapter will focus on those 
producing an optical/luminescent signal.  Optical signals are easily measured, 
and an extensive array of instrumentation is available, ranging from very 
sophisticated, state-of-the art to less complex, cost-effective hardware depending 
on the needs of a particular application.  Additionally, a great variety of 
luminescent proteins have been well-characterized.[1, 5]  A summary of the 
attributes of a variety of luminescent reporter proteins can be found in table 1.1.  
Following is a discussion of each of the types of luminescent reporter proteins 
and enzymes capable of generating an optical signal when employing an 
appropriate substrate. 
 
A. Luciferases 
 The term luciferase encompasses a class of enzymes that catalyze a 
reaction in which a substrate known generically as a luciferin reacts with oxygen 
to produce light.  These enzymes offer excellent limits of detection, largely in part 
because there is no background luminescence from endogenous activity in other 
organisms or from the media and samples in which the measurements are being 
taken.  The high quantum efficiency of the bioluminescent reactions catalyzed by 
these enzymes also contributes to the low detection limits that they afford.  Given 
that luciferase emits light via a biochemical reaction, there is no need for an 
excitation source, making the instrumentation needed for measuring 
bioluminescence simple and cost-effective.  These are clear advantages of  
11 
 
Table 1.1 Common Reporter Proteins and their Characteristics. 
Reporter Protein 
[reaction catalyzed] 
Detection Method  
Advantages Disadvantages 
Bacterial Luciferase 
[FMNH2 + R-CHO + O2  
FMN + R-COOH + H2O + hv (490 
nm)] 
Bioluminescence 
High sensitivity.  May not 
require substrate. No 
endogenous activity in 
mammalian or bacterial 
cells.  No light source 
needed. 
Heat Labile.  Narrow 
linear range.  Requires 
aerobic environment. 
 
Firefly Luciferase 
[Firefly luciferin + ATP + O2 + 
Mg2+ Oxyluciferin + AMP + Pi + 
hv (560 nm) 
Bioluminescence 
High sensitivity.  Broad 
linear range.  No 
endogenous activity in 
mammalian or bacterial 
cells.  Spectral variants 
available.  No light source 
needed. 
Requires substrate.  
Requires aerobic 
environment and ATP.  
Requires solubilizers for 
substrate permeability 
into cells. 
Renilla Luciferase 
[Renilla coelenterazine + O2 
Coelenteramide + CO2 + hv (480 
nm) 
Bioluminescence 
No endogenous activity in 
bacterial or mammalian 
cells.  No light source 
needed.  Required 
Substrate is membrane 
permeable 
Requires substrate and 
may require cell lysis. 
Aequorin 
[Jellyfish coelenterazine + O2 + 
Ca2+ Coelenteramide + CO2 + 
hv (465 nm) 
Bioluminescence 
High sensitivity.  No 
endogenous activity in 
mammalian or bacterial 
cells.  No light source 
needed.  
Requires substrate and 
the presence of Ca2+. 
Green Fluorescent Protein 
[Formation of an internal 
chromophore 
Excitation/Emission:  395 nm/509 
nm] 
Fluorescence 
Autofluorescent.  No 
substrate or cofactors 
needed.  Spectral 
variants available.  No 
endogenous activity in 
most systems.  Stable at 
physiological pH. 
Moderate sensitivity.  
Background fluorescence 
from some samples may 
interfere.  Toxic to some 
cell types.  Formation of 
chromophore can be 
slow. 
β-Galactosidase 
[Hydrolysis of β-Galactosides] 
Chemiluminescence 
Fluorescence 
Colorimetric 
Electrochemical 
Sensitive and stable. 
Moderate linear range.  
Can be used in anaerobic 
environment 
 
Endogenous activity.  
Requires substrate. 
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luciferases over other luminescent systems such as those based on fluorescence 
and therefore, make this family of enzymes great candidates for use as reporters. 
 Luciferases have been isolated from a number of organisms, which 
include fireflies, bacteria, worms, fungi, etc.  Commonly used as reporter genes 
in bacterial cell-based biosensing systems are those isolated from bacteria 
including members of the genera Vibrio, Xenorhabdus, and Photobacterium.[1]  
In these organisms, bioluminescence is conferred by the lux operon which is 
comprised of luxCDABE gene cassette.  Of the five genes in the lux operon, only 
lux A and lux B (with the addition of a suitable substrate) are required for 
bioluminescence.  The products of these two genes form the catalytically active 
dimer, which oxidizes a long-chain aliphatic aldehyde (luciferin) and a reduced 
flavin mononucleotide (FMNH2) cofactor to the corresponding carboxylic acid and 
FMN, respectively.  During this process, an unstable complex containing an 
excited oxide bond is formed, which relaxes to the ground state and the 
concomitant emission of light at 490 nm.[6] 
 While the luxAB genes alone, employed as a reporter, are enough to 
produce bioluminescence, the addition of a long-chain aldehyde substrate, 
usually decanal, is required unless the entire luxCDABE gene cassette is 
present.  The enzyme products of the remaining genes in the cassette, lux C, lux 
D, and lux E provide the aldehyde substrate needed for bioluminescence.  
However, it has been noted that the use of luxABalone results in increased 
bioluminescence and, consequently, improved sensitivity of measurement in a 
biosensing system.[7]  This is likely the result of limited substrate production from 
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the products of the lux cassette as opposed to the excess of substrate added 
when luxAB is used.  The design of a cell-based biosensing system using the 
luxCDABEis advantageous in the development of simplified assays and 
applications to be used in real-time monitoring.  For applications requiring 
increased sensitivity or improved control over when the generation of the 
bioluminescence signal occurs, the luxAB reporter gene is preferred. 
 In addition to bacterial luciferases, firefly luciferase has also been well-
characterized and widely used as a reporter gene.  Firefly luciferase is a 62 kDa 
monomer that catalyzes the oxidation of a benzothiazolyl-thiazole luciferin to 
oxyluciferin in the presence of ATP, oxygen, and Mg2+.  The oxyluciferin 
produced is an excited molecule that subsequently relaxes to a ground state 
resulting in the emission of light at a maximum wavelength of 550-575 nm.  
Firefly luciferase has approximately 10-fold higher quantum yield than bacterial 
luciferase, which endows it with a broad dynamic range (7-8 orders of 
magnitude).[8, 9]  Additionally, mutagenesis of firefly luciferase has resulted in 
enzymes that emit light at wavelengths in a wider range of the visible spectrum 
allowing for the development of multiplexed analysis.[10]  Examples of these 
include red-shifted, thermostable variants of luciferase from Photinuspyralis.[11]  
However, the need for the addition of a substrate and the requirement for ATP 
can, in some cases, limit the application of firefly luciferase. 
 Another luciferase well-studied as a bioreporter was isolated from the 
marine organism Renilla reniformis, a species of sea pansy.  Renilla luciferase is 
a 31 kDa monomeric enzyme that catalyzes the oxidation of coelenterazine and 
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results in the emission of light at 480 nm.[12]  The sensitivity and dynamic range 
of Renilla luciferase is similar to that of firefly luciferase; however, Renilla 
luciferase is not as widely used as a bioreporter.[5, 13]  In applications where 
multiplexing or a dual-reporter based system is desirable this luciferase is 
sometimes used along-side firefly luciferase as they have distinctwavelengths of 
emission.  However, the need for substrate addition and cell lysis make using 
either firefly or Renilla luciferases less appealing than bacterial luciferase since 
increased cost, time, and error is introduced as a result. 
 Luciferases from other organisms have been successfully used as 
bioreporters in cell based sensing systems.  In work by Wu et al., a dual-reporter 
system was constructed by transforming NIH 3T3 fibroblast cells with a plasmid 
containing Cypridina luciferase (CLuc) fused to a target gene and a plasmid 
containing Gaussia luciferase (GLuc) as a control plasmid to monitor gene 
expression in these cells.[14]  Both CLuc and GLuc are secreted into the growing 
medium upon expression and emit at different wavelengths (460 nm and 480 nm, 
respectively), allowing for simultaneous measurement without cell lysis. 
 The variety of luciferases is increasing as novel proteins are being 
identified and integrated as reporters into cell-based sensing systems.  For 
example, the recently characterized luciferases from the organisms 
Luciolaitalica[15]and Phrixothrixhirtus[16] are expanding the palette of emission 
wavelengths available when selecting reporter proteins.  Two other novel 
luciferases from the marine copepod, Metridiapacifica, are thermostable 
bioluminescent proteins with distinct emission kinetics and are efficiently 
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secreted into culture medium upon expression as a result of the presence of an 
N-terminal signal peptide.[17]  Because these are secreted into the culture 
medium, they could be incorporated into a cell-based sensing system and 
continuously monitored in a portion of culture medium independent of cell lysis. 
 
B. Aequorin 
 Aequorin is a 22 kDa photoprotein native of the marine jellyfish Aequorea 
victoria.  The emission of bioluminescence by aequorin is different from that of 
the luciferases, including Renilla luciferase.  Aequorin needs an organic 
imidopyrazine substrate, coelenterazine, and the presence of Ca2+ for emission 
of bioluminescence.  Coelenterazine resides within a hydrophobic pocket within 
the structure of the protein, while Ca2+ binds to three conserved EF-hand regions 
of aequorin.  It is the binding of aequorin to Ca2+ that causes the protein to 
undergo a conformational change, which causes coelenterazine, in the presence 
of molecular oxygen, to go through an excited state from which it relaxes to form 
coelenteramide and emit bioluminescence at 460-470 nm.[1]  The emission from 
aequorin follows flash-type kinetics with an emission from the native protein 
lasting about 3 seconds and a quantum yield of 0.15.[18]  Mutagenesis of 
aequorin has led to the development and characterization of mutants with tuned 
emission lifetimes and altered wavelengths allowing for multiplexing in both time 
and spatial (wavelength) domains.[19]  While aequorin has found some 
application in cell-based biosensing systems, its use has been somewhat limited, 
due mostly to its sensitivity to the presence of calcium ions and the need for the 
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addition of a substrate.  In spite of these limitations, aequorin has been employed 
in high-throughput screening assays where its sensitivity to calcium is imperative 
in the study of G-protein coupled receptors and in screening compounds that act 
as their agonists or antagonists.[20]  Also, the detection of specific pathogens, 
such as Yersinia pestis and Bacillus anthracis, has been achieved using a 
sensing system named CANARY (Cellular Analysis and Notification of Antigen 
Risks and Yields).[21]  This system is constructed by engineering B cells that 
express both aequorin as a bioreporter and membrane-bound antibodies for the 
pathogen of interest.  Even when exposed to low levels of pathogen, the 
antibodies are capable of recognizing their target.  The resulting binding event 
triggers an increase in intracellular calcium concentration, which leads to the 
subsequent bioluminescence emission by aequorin within seconds.  Novel 
relatives of aequorin, such as the photoprotein, clytin, from Clytia gregarium have 
been recently characterized and found to be less sensitive to calcium ions.[22]  
The availability of spectral variants for multiplexing, exceptional sensitivity (in the 
sub-attomole range), and lack of endogenous expression in other organisms 
warrants consideration of aequorin as a reporter gene. 
 
C. Green Fluorescent Protein (GFP) 
 Like aequorin, the green fluorescent protein originates from the jellyfish 
Aequorea victoria.  However, unlike the bioluminescent reporter genes 
mentioned thus far GFP emits fluorescence.  Native GFP is a 238 amino acid 
protein possessing a β-barrel structure containing an internal fluorescent 
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chromophore.  This chromophore is formed from three amino acids (threonine 
65, tyrosine 66, glycine 67) in the interior of the protein by cyclization and 
oxidation of the tripeptide upon proper protein folding.  The exceptional stability 
of GFP allows for the accumulation of reporter protein, which is particularly 
relevant when used in bacterial cell-based biosensors employing a weak 
promoter.  GFP does not require a substrate to fluoresce, however as with any 
fluorescent reporter, it requires irradiation at its excitation wavelength maximum 
of 395 nm, resulting in light emission at a wavelength of 509 nm with a quantum 
yield of 0.88.[6, 23]  Extensive research has generated a large number of GFP 
mutants with altered excitation and emission maxima, stabilities, and signal 
intensities.[8, 24, 25]  GFP is also tolerated by a variety of cell types, including 
mammalian and bacterial cells.  However, because of interference from 
background fluorescence in samples, the detection limits afforded by GFP are 
not comparable with those of bioluminescent proteins such as the luciferases or 
aequorin.[1] 
 
D. β-Galactosidase 
 The gene product of the lacZ gene from Escherichia coli is β-
galactosidase, an enzyme whose biological function is to cleave lactose into 
galactose and glucose, although it has been shown that the enzyme may act on 
a variety of substrates.  Depending on the substrate employed, β-galactosidase 
can generate a fluorescent, chemiluminescent, colorimetric, or electrochemical 
signal.[25]  For the production of chemiluminescence signals, 1,2-dioxetane 
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derivatives are typically used as a substrate.  As a reporter gene, lacZ can afford 
detection limits as low as 2 fg with a dynamic range of 5-6 orders of 
magnitude.[1, 5]  Despite these advantages, the need for the addition of a 
substrate and the requirement for cell lysis to make the substrate available to the 
enzyme restrict the use of lacZ as a reporter gene for certain specialized 
applications. 
 
ADVANTAGES AND LIMITATIONS OF CELL-BASED BIOLUMINESCENT 
BIOSENSORS 
 The continuous discovery of new reporter molecules and recognition 
elements by biologists along with advancement in the field of recombinant DNA 
broadens the range of types of sensors that can be developed with regard to 
selectivity, sensitivity, and parallel analysis.  Moreover, the identification and 
investigation of organisms that can be employed and survive in extreme 
environments, such as extremophiles and spore-forming microorganisms, should 
result in systems that present expanded storage and working conditions and are 
more resilient to extreme settings.  This improved ruggedness and storage of 
cell-based biosensors should make them more amenable to field-portable 
environmental and clinical applications.[26] 
 Uniquely among biosensing systems, cell-based systems can provide 
significant information regarding the bioavailability of the compound being 
interrogated.[27]  When employing an intact cell in the sensing system, the 
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compound being detected must be transported into the cell and activate certain 
cellular processes and pathways in order to produce a response.  In this regard, 
a cell-based sensing system can identify those species, to be transported across 
the cell membrane.  This information is especially useful in determining relevant 
toxicological characteristics of complex mixtures in which some components may 
be bioavailable while others may not.  The bioavailable concentration of a 
species as detected using a cell-based biosensor is often related to the total 
concentration determined by standard physicochemical analysis to better 
characterize the sample being analyzed.[28] 
 While these advantages warrant further study and development of cell-
based biosensing systems, there are a number of limitations that must be 
overcome before their full potential as an analytical method can be realized.  
Inherent to all biological systems is some degree of variability; cell-based 
biosensing systems are not immune to this.  This variability can result from 
growth of the cells in non-ideal conditions, response to various components in 
complex samples, or a number of other unidentified factors.  This variation can 
contribute to inter- and intra-assay variability.  To address this issue, cell-based 
systems have been developed that carry a secondary plasmid in which a unique 
reporter protein is under the control of a constitutive promoter.[29]  This allows 
for the response from the analyte-inducible promoter to be normalized with 
respect to cell growth and metabolism. 
 As previously mentioned, cell-based biosensing systems provide 
bioavailability information.  However, when bacterial whole-cell sensing systems 
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are employed, this does not lead to a direct correlation to all relevant 
toxicological information as it applies to higher organisms such as humans.  This 
can be addressed by the development of biosensing systems based on more 
complex cell types such as yeast or mammalian cells, thus giving data that is 
more applicable to these more complex organisms.  Also, further study of 
similarities in biochemical pathways between cell types used in biosensing 
systems and cells present in higher organisms may lead to more accurate 
extrapolation of relevant toxicological data. 
 Finally, there can be some degree of instability in the plasmid DNA within 
cell-based sensing systems resulting in decreased reproducibility of 
measurement.  This can occur as the cells carrying the exogenous genetic 
material reproduce and replicate the plasmid DNA contained within them.  While 
the rate of error is very low, some mutations can occur.  To negate this effect, 
plasmid DNA can be integrated into the chromosome of the cells being used, 
resulting in increased genetic stability. 
 
APPLICATIONS OF CELL-BASED BIOSENSING SYSTEMS 
 The distinct properties and advantages discussed previously have allowed 
the application of cell-based biosensing systems in different fields.  The use of 
bioluminescent reporters allows for compact, portable instrumentation due to the 
lack of need for an excitation source, a requirement in fluorescence 
measurements.  In addition, bioluminescent bioreporters lack the background 
signal deriving from fluorescence generated by other components in the sample 
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matrix when exciting fluorescent reporters, which contributes to their superior 
sensitivity.  Many specific examples can be found throughout the current 
literature describing applications in the realm of on-site environmental monitoring, 
drug candidate screening, clinical testing, high-throughput screening, etc.  
Recent examples of these applications will be highlighted here in more detail.  
Additionally, a number of bacterial cell-based biosensing systems are 
commercially available; examples of these are shown in table 1.2. 
 Cell-based biosensors have been engineered that can determine factors 
such as general stress, oxidative stress, and genotoxicity.  In these constructs, a 
reporter gene is placed under the control of a promoter capable of responding in 
a dose-dependent manner to one of these stressors.  Such systems have been 
developed to monitor oxidative stress,[2, 30] protein damage,[30, 31] DNA 
damage,[2] among others. 
 Bacterial cell-based biosensors are commonly used in environmental 
monitoring.  Typically, soil and water samples concerning environmental 
contamination are complex in nature, containing both naturally occurring and 
foreign components.  The specificity of the biological recognition element in a 
cell-based biosensing system is ideally suited for detecting a desired compound 
in a complex mixture.  To that end, biosensors have been developed for a variety 
of analytes ranging from metals to organic pollutants and representative 
examples of these are discussed below. 
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Table 1.2 Commercially available bacterial cell-based biosensing systems 
 
Product Name 
[Responds To] 
Description Manufacturer Reference 
Microtox™ 
[General Toxicity] 
Inhibition test based 
on freeze dried V. 
fischeri 
Strategic 
Diagnostics, 
Inc. 
http://www.sdix.com/ 
Mutatox™ 
[Mutagenic 
Toxicity] 
Engineered dark 
variant of V. fischeri 
recovers 
luminescence 
restored upon 
exposure to 
mutagenic 
compounds 
Strategic 
Diagnostics, 
Inc. 
http://www.sdix.com/ 
BIOMET™ 
[Zn, Cd, Cu, Ni, 
Pb, Cr, or Hg] 
Engineered, metal-
tolerant 
Ralstoniametalliduran
s produces luciferase 
in response to metals 
Vito http://wwwa.vito.be/english
/index.htm 
Cellsense™ 
[Chlorophenols, 
other organics] 
Engineered E. coli 
produces 
amperometric 
response to analytes 
 Farre, et al.[32] 
BioTox™ 
[General Toxicity] 
Inhibition test based 
on freeze dried V. 
fischeria tailored for 
sediment samples 
Aboatox http://www.aboatox.com/ 
LumiStox™ 
[General Toxicity] 
Inhibition test based 
on frozen V. fischeria 
Hach Lange http://www.drlange.com 
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There are a number of reports in the current literature regarding cell-based 
assays for the detection of inorganic analytes, specifically metals.  The design of 
these biosensors is based upon the use of regulatory elements from 
microorganisms, which natively regulate the expression of genes to confer metal 
resistance, to control the expression of a bioreporter instead.  Sensing systems 
have been developed for a variety of environmentally relevant toxic metals and 
metalloids including mercury,[33-35] antimonite/arsenite/arsenate,[36-39] 
cadmium,[36, 40, 41] chromate,[42] and aluminum[43] among others.  In 
addition, inorganic compounds, such as nitrate, have been detected using cell-
based sensing systems.[44]  Detection limits as low as femtomolar with analysis 
times as short as 30 min have been reported for these species.  Progress 
towards the development of a portable biosensing system for the detection of 
metals has been achieved by the engineering of a fiber-optic device consisting of 
mercury and arsenic sensing bacterial biosensors immobilized on optical 
fibers.[45]  Environmentally relevant detection limits were obtained using this 
biosensing system:  2.6 µg/L for mercury, 141 µg/L for arsenic(V), and 18 µg/L 
for arsenic(III). 
 Cell-based biosensing systems have been developed for a number of 
organic compounds including endocrine disrupting compounds (EDCs), 
polychlorinated biphenyls (PCBs) and their metabolites, phenol, catechols, 
naphthalene/salicylic acid, benzene/toluene/ethylbenzene/xylene, etc.[5, 46-52]  
Many of these compounds are nearly ubiquitous in the environment and pose 
negative health effects on many organisms, including humans.  They share 
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structural similarities and biological activities with naturally occurring compounds 
such as hormones.  Traditional quantification of these compounds from 
environmental samples involves extensive sample pretreatment, derivatization, 
and extraction prior to detection by a suitable instrumental method.  In addition to 
environmental samples, it has been demonstrated that a number of varied 
analytes can be detected in biological samples such as blood serum, making 
whole-cell sensing systems useful in the detection of biomarkers of exposure as 
well.[4] 
 Rather recently, cell-based biosensors have been developed for quorum 
sensing signaling molecules, the integral elements of the bacterial 
communication system.  Quorum sensing is a phenomenon in which certain 
bacteria communicate by producing, secreting, sensing and responding to 
signaling molecules.  The concentration of these molecules correlates to the 
density of the cells.  This cell-to-cell communication allows the organisms to 
control the expression of specialized proteins depending on the cell population 
size.  Since bacterial processes, such as, production of virulence factors, 
formation of biofilms and ability to colonize a certain environment are regulated 
by quorum sensing, the detection and quantification of quorum sensing signaling 
molecules may be relevant in the investigation of the status of a variety of 
diseases that have been linked to bacteria.[53]  Cell-based biosensors have 
been developed by placing the expression of a bioreporter under the control of 
promoters and associated recognition/regulatory proteins from bacterial quorum 
sensing regulatory systems that respond to the presence of quorum sensing 
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molecules.[54]  Successful use of these sensors has also been demonstrated in 
biological samples such as saliva and stool.[55] 
 Cell-based biosensors also exist for a number of antibiotic compounds.  
As the use of antibiotics increases, antibiotic resistance mechanisms in 
microorganisms are becoming increasingly widespread.  Antibiotics are also 
being found in environmental and food samples; for instance, they have been 
detected in chlorinated drinking water at trace levels (down to µg/L levels).[56]  
Conventional methods to detect antibiotics rely on immunoassays, 
chromatographic methods, and microbial growth inhibition tests.  Because of 
their unique properties, especially the ability to characterize the bioavailability of 
an analyte, cell-based biosensors are well-suited for these applications.  Such 
biosensors have been developed for the detection of antibiotics in various types 
of samples such as water and food products,[57]as well as blood and serum.[58]  
Cell-based biosensors have been used for the determination of antibiotic activity 
on a number of biochemical pathways in tandem with the screening of natural 
products for antibiotic activity.  For example, a panel of five gene promoter 
regions from the soil bacterium Bacillus subtilis, which have altered mRNA 
expression profiles upon antibiotic exposure, were fused to a firefly luciferase 
reporter gene.[59]  These genes, yorB, yvgS, yheI, ypuA, and fabHB, participate 
in biosynthetic pathways such as the synthesis of DNA, RNA, proteins, cell wall, 
and fatty acids, respectively.  Biosensors based on the use of these genes along 
with luciferase have been used in a high-throughput screening mode to 
investigate the antibiotic activity of 14,000 natural products.  Bacterial cell-based 
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biosensors have also been developed to examine the microbicide activity of 
some antibacterial polymers.  Luminescence produced by the E. coli strain 
O157:H7 modified to express bacterial luciferase via the luxCDABEgene was 
monitored upon exposure to polymer compounds to determine bactericidal 
properties.[60]  Bacterial biosensors also exist for the screening of antimicrobial 
activity of compounds in the gas phase that may find use in sterilization 
procedures.  To that end, the bioluminescent bacterium Pseudomonas 
fluorescens 5RL was immobilized on a 0.2 µm membrane filter and exposed to 
varying concentrations of chlorine dioxide gas.  In this system, a decrease in 
luminescence was correlated to increased antimicrobial activity of the gas.[61] 
 The detection of other biologically relevant molecules, such as sugars has 
also been achieved using a cell-based biosensor approach.  Cell-based 
biosensing systems have been developed for a number of sugars by placing the 
expression of a reporter gene under the control of a promoter and regulatory 
protein responding to the desired sugar.  For example, cells have been 
engineered to detect arabinose,[3, 62] glucose,[63] sucrose,[63] and lactose[3, 
63].  Multi-analyte detection has been demonstrated with these compounds with 
the simultaneous detection of lactose and arabinose using a single biosensing 
organism in which two variants of GFP with distinct emissions were used 
asreporters for each sugar.[3]  Cell-based biosensors are especially useful in the 
detection of sugars as they proved certain advantages over conventional 
detection methods.  For example, detection of sugars using electrochemical 
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methods often suffer from a lack of specificity and those based on spectroscopic 
methods require derivatization of sugar with a chromophore substrate. 
 Applications of bacterial cell-based biosensors can also be found in the 
field of molecular biology.  The luxCDABE cassette from Photorhabdus 
luminescens was cloned into a pCRII vector and transformed into E. coli.  The 
resulting cells were then grown with varying concentrations of lytic bacteriophage 
T4 at varying temperatures.  The bioluminescence was monitored with respect to 
time, and as the bacteriophage lysed the bacteria a decrease in bioluminescent 
was observed.  The results allowed the quantitation of the bacteriophage as well 
as determination of its thermal deactivation conditions.[64] 
 In the field of medicine, genetically engineered bacterial cell-based 
biosensors have found applications in imaging in vivo and in vitro.  E. coli 
engineered to express GFP in response to quorum sensing molecules, N-
acylhomoserine lactones (AHLs), were introduced into mice that had been 
infected with Pseudomonas aeruginosa, an opportunistic pathogen that uses 
these molecules for intercellular communication.[65]The lung tissue from the 
mice was examined by confocal scanning laser microscopy and the pathological 
damage observed was correlated to fluorescence measured as a result of 
increased AHL levels from bacterial presence.  E. coli that migrate preferentially 
to tumor tissue, harboring a plasmid containing the luxCDABE cassette, were 
injected into mice with CT26 mouse colon cancer and the subsequent bacterial 
migration was imaged by detection of bioluminescence from the luciferase 
expressing bacteria.[66]  The ability to image tumors in vivo in a non-invasive 
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manner is a valuable tool when diagnosing and monitoring the spread of a 
different types of cancer, as well as when screening for novel antitumor drugs.  
Rather recently, Foucault et al., engineered E. coli to express either bacterial 
luciferase or mutants of firefly luciferase that were employed for real-time in vivo 
monitoring of infection in mice.[67]The use of bioluminescent bacterial 
biosensors in these applications offers a number of advantages, perhaps the 
most important being thelower detection limits due to the lack of background 
emission associated with similar methods employing fluorescent reporters. 
 
DESIGN STRATEGIES OF PROTEIN-BASED BIOSENSORS 
 Protein-based biosensors, in contrast to cell-based biosensors, consist of 
an isolated protein as the recognition element coupled directly to a signal 
transducing element.  The protein employed can be a small-molecule 
binding/transport protein, an antibody, a regulatory protein, an enzyme, or a 
small peptide fragment derived from functional proteins.  The signal output for 
these biosensing systems can be electrochemical[68, 69], fluorescent[70], 
phosphorescent[71], bioluminescent[72], or piezoelectric[73], etc.  The work 
discussed here will focus on those protein-based biosensing systems with an 
optical (fluorescence/bioluminescence) signal output.  Because isolated proteins 
are employed, the assay time is limited only by the timescale of the 
recognition/binding event, leading to shorter assay times when compared to cell-
based biosensing systems.  Additionally, much of the natural variability inherent 
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in using metabolically active whole-cells as a sensing element can be reduced or 
eliminated when using isolated proteins. 
 Protein-based sensing systems can be broadly placed in two categories:  
genetically-encoded biosensing systems and chemically-modified biosensing 
systems (Figure 1.4).  In the genetically encoded approach, the protein is 
engineered in such a way that the isolated product contains both the recognition 
element and the transducing element without need for further modification.  A 
typical example of a genetically encoded biosensing system is a fusion of a 
ligand binding protein to reporter protein, such as GFP, in which a change in 
fluorescence is observed upon ligand binding.  Chemically-modified biosensing 
systems must be further modified after the protein purification step.  Usually, a 
sensing protein is modified by covalent attachment of a small reporter molecule.  
An example of a chemically-modified protein-based sensor is a ligand binding 
protein in which an organic fluorophore is covalently attached to a site on the 
protein such that a change in fluorescence can be measured upon ligand 
binding.  Following is a more in-depth discussion of each of these types of 
sensing systems. 
 
A. Genetically-encoded Biosensing Systems 
 Genetically encoded protein-based biosensing systems generally consist 
of a single protein or a fusion of two or more proteins that, upon purification, 
contains both the sensing and transducing elements without the need for further 
modification.  The most common application for these systems is for in vivo  
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imaging for the monitoring of various cellular processes, and there are myriad of 
examples in the literature for their uses.[74, 75]  Genetically-encoded systems 
are uniquely suited for imaging applications because their spatiotemporal activity 
can be tailored based on the selection of proteins used as the molecular 
recognition element and reporter.  However, these systems have also found 
some application in in vitro sensing applications due to relative ease of design 
and preparation when compared to chemically-modified biosensors.[72, 76] 
 There are a number of well-studied strategies used in the development of 
genetically-encoded biosensing systems (Figure 1.5).  The most common 
reporter molecules employed in the design of genetically-encoded systems are 
GFP and its variants and aequorin, thus the examples discussed herein will focus 
on these proteins.  In the first strategy, an intramolecular Förster Resonance 
Energy Transfer (FRET) approach is used.  Briefly, FRET is a phenomenon in 
which a donor molecule is excited and then nonradiatively transfers a portion of 
its excited-state energy to a proximal (typically 10-100 nm) acceptor molecule 
which is in turn promoted to an excited state and undergoes fluorescence.  Upon 
analyte binding, a conformational change occurring in the binding region results 
in a change in the distance between the donor and acceptor.  This change in 
distance manifests as a change in FRET efficiency resulting a change in 
signal.[77]  The second strategy is also FRET-based, but relies instead on an 
intermolecular FRET approach.  In this strategy, the donor and acceptor are 
located on two different proteins.  Upon the binding or association of these two 
proteins, the donor and acceptor are brought closer together, leading to an  
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increase in FRET.  This approach is most applicable to studies of protein-protein 
interactions.[78]  The third strategy is referred to as bimolecular complementation 
or simply as the “molecular switch” approach.  In this design, a fluorescent or 
bioluminescent protein is rationally designed such that the amino acid sequence 
is split into two truncated fragments which, upon being placed within proximity of 
one another, can reassemble to form a functional reporter protein.  Each 
fragment of the reporter molecule can then be fused to either end of a sensing 
protein such that upon analyte binding, the complimentary fragments are either 
pulled apart or brought together, resulting in a decrease or increase in signal, 
respectively.[72, 79]  The fourth strategy is a variation of the third strategy in 
which truncated fragments of a sensing protein are placed at either end of an 
intact reporter protein.  In this strategy, the binding event causes the sensing 
protein to reassemble which perturbs the structure of the reporter protein, thus 
resulting in a change in signal.  In the fifth strategy, the reporter protein itself is 
engineered such that it displays a change in signal upon response to desired 
stimuli without the need for an exogenous sensing protein.[80-82]  The sixth and 
final strategy is an extension of the fifth in which the sensing protein produces a 
measurable change in signal without the need for an exogenous reporter protein.  
Typically, this is accomplished by monitoring changes in intrinsic tryptophan 
fluorescence in a protein upon interaction with an analyte.[83, 84] 
 
B. Chemically-modified Biosensing Systems 
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 In contrast to genetically encoded protein-based biosensing systems, 
chemically-modified biosensors, as their name suggests, must be altered in 
some way after isolation of the sensing protein.  Typically, this is accomplished 
by the covalent attachment of a small fluorescent organic molecule at a location 
within the protein structure which experiences a change in conformation upon 
ligand binding.  As a result, the ligand-binding event causes a change in the 
microenvironment around the environmentally-sensitive fluorophore, resulting in 
a change in measured fluorescence intensity.  Site-specific modification of 
proteins is most commonly accomplished by engineering the protein to contain a 
unique cysteine residue within the protein at the desired location and subsequent 
modification by a fluorophore using well-established sulfhydryl-reactive 
chemistry.  The carefully-selected fluorophore can be sensitive to changes in pH, 
polarity, hydrophobicity, or other factors.  As an alternative approach, a FRET-
based strategy can be employed in which a sensing protein is modified with two 
fluorophores, a donor/acceptor pair, such that the ligand binding event alters the 
distance between the donor and acceptor resulting in a change in FRET.  In this 
strategy, either the donor or acceptor can also be a genetically encoded reporter 
such as GFP or one of its variants. 
 The phenomenon of the alteration of fluorophore response in regards to its 
microenvironment is termed solvatochromism.  These changes in fluorescence 
intensity can result from a number of factors including solvent polarity and 
viscosity, rate of solvent relaxation, probe conformational changes, rigidity of the 
local environment, internal charge transfer, proton transfer and excited state 
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reactions, probe-probe interactions, and changes in radiative and non-radiative 
decay rates.[85]  When a fluorophore is bound to a location within a protein that 
undergoes a dramatic conformational change, one or more of the factors above 
may be altered, thus altering the spectral characteristics of the fluorescence 
emission (intensity, lifetime, wavelength maxima, etc).  Because of the 
complexity of these processes, it is often difficult to determine the contribution of 
each of these factors to the change in the fluorescence that results from a 
change in protein conformation.  Regardless, if this change in fluorescence 
emission follows a concentration-dependent response to the ligand, then this 
chemically-modified protein can be used for the development of a biosensing 
system. 
 Because these organic fluorophores are typically small molecules, this 
approach has the advantage of introducing a less pronounced disturbance in the 
sensing protein than the genetic fusion to a large reporter protein, thus there is a 
reduced chance of a detrimental effect on the activity of the sensing protein.  
Additionally, the variety of commercially-available fluorophores allows for the 
tailoring of spectral properties (wavelength, lifetime, quantum yield, etc) of the 
biosensing system.  While some degree of customization is possible for 
genetically-encoded systems, the availability of mutants of reporter proteins with 
varying spectral properties is more limited. 
 
SELECTION AND DESIGN OF MOLECULAR RECOGNITION ELEMENTS 
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 Integral to the design of a protein-based sensing system is a molecular 
recognition element capable of accurately detecting the desired analyte with 
appropriate sensitivity and selectivity.  As mentioned above, many types of 
proteins can be employed in the design of a protein-based sensing system.  
Among these are chemotaxis/transport proteins, antibodies, enzymes, regulatory 
proteins, etc.  Each of these types of proteins has been employed in the 
development of biosensing systems using different strategies to take advantage 
of their unique characteristics and advantages. 
 
A. Chemotaxis/transport Periplasmic Binding Proteins 
 Periplasmic binding proteins (PBPs) have been explored thoroughly as 
recognition elements for use in protein-based biosensing systems.  PBPs 
function as transporters for their specific ligands across the periplasmic space.  
In general, members of this protein family selectively bind their respective target 
ligands with binding affinities in the 0.01-10 µM range.[86]  Although there is 
great variety in their ligand specificity and amino acid sequence, these proteins 
typically have an overall conserved structural motif.[87]  In general, PBPs consist 
of two globular domains each consisting of a β-sheet region surrounded by α-
helices and connected by a short “hinge” region.  (Figure 1.6)  The region 
between the two domains forms a binding pocket in which the ligand binds, 
triggering an overall hinge-motion conformational change in the protein.  PBPs 
and their derivatives have been identified for a wide-array of small molecules 
including sugars[72, 88-90], metal ions[90, 91],amino acids[92],  
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sulfate/phosphate[90], etc.  The diversity of PBPs, their inherent selectivity, their 
ease of expression and purification, and the customizability of their binding 
characteristics have contributed to the intense interest in recent years regarding 
their use as recognition elements in biosensing systems. 
 
B. Antibodies 
 Antibodies, or immunoglobulins, are specialized proteins produced by the 
immune systems of animals to recognize a foreign target called an antigen.  
Generally, they are depicted as having a “Y”-shaped structure, with the antigen 
binding sites located at the end of each arm of the protein (Figure 1.7).  In its 
most basic form, the antigen/antibody interaction can be thought of as a lock-
and-key interaction.  Antibodies are generally produced by injecting an animal 
with the antigen of interest, allowing time for the animal’s immune system to 
produce antibodies as part of a natural immune response, and then harvesting 
the appropriate antibodies by various methods.  This well-defined procedure 
allows the production of antibodies with exceptional selectivity and affinity to a 
great variety of antigens ranging from small molecules to entire proteins and 
microorganisms.[93, 94] 
 Antibodies have been widely used as a molecular recognition element in 
numerous biotechnology and biosensing applications.  Perhaps the most 
common and widely used application is that of enzyme-linked immunosorbent 
assays (ELISA).  There are many variations of ELISA, however in the most basic  
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strategy, a sample with an unknown amount of analyte/antigen is immobilized on 
a surface (usually a microtiter plate), and then the sample solution is removed 
and the surface is washed.  Next, a solution containing a non-specific protein, 
typically bovine serum albumin, is added to coat the exposed surface not 
covered by the sample.  Then a primary antibody with an antigen binding site for 
the analyte is added and allowed to bind to the analyte on the surface.  A 
secondary antibody, with an enzyme attached to it, is added next, which 
recognizes the primary antibody and binds to it.  Finally, an appropriate substrate 
for the attached enzyme is added in order to produce an observable signal which 
corresponds to the concentration of analyte/antigen present in the initial sample.  
Most commonly, an enzyme-substrate pair is chose which results in a 
colorimetric signal.  However, alternative approaches employing bioluminescent 
photoprotein such as aequorin[19], fluorescent proteins such as GFP and its 
variants[95] or fluorophore-labeled antibodies also exist.    
 
C. Enzymes 
 Enzymes are a class of proteins which catalyze biochemical reactions by 
reducing the activation energy.  Within the active site of an enzyme, a substrate 
binds and is converted to a product.  In complex biological systems, enzymes 
must have exceptional specificity towards their appropriate substrate and an 
affinity to their substrate at biologically relevant concentrations.  These 
characteristics make enzymes amenable for use in the development of 
biosensing systems.  Indeed, perhaps the most commercially successful 
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example of a protein-based biosensing system, the personal blood glucose 
meter, is an enzyme-based system usually employing the enzyme glucose 
oxidase.[96]  The current generation of glucose meters are electrochemical-
based sensors which employ glucose oxidase and a mediator coupled to an 
electrode for electrochemical measurement. 
 In addition to electrochemical approaches, fluorescence-based 
approaches are also being pursued in the development of enzyme-based 
biosensors.  Enzyme activity is also often associated with a significant 
conformational change which can be utilized in the development of a chemically-
modified biosensor.  This has been used in the development of a biosensor for 
glucose based on the enzyme glucokinase by site-specific attachment of a 
fluorophore.[97]Glucokinase functions by transferring phosphate from ATP to the 
C6 position on glucose.  During this enzymatic reaction, a large conformational 
change occurs.  This conformational change can be observed as a change in 
fluorescence when the enzyme is modified with an appropriate fluorophore.  In 
addition, some enzymes require the binding of a cofactor in addition to a 
substrate.  In the case of glucose oxidase, the cofactor flavin adenine 
dinucleotide which is fluorescent and displays a small change in fluorescence 
upon glucose binding.[98] 
 
D. Regulatory Proteins 
 Regulatory proteins, as discussed in some detail above, can also be used 
in the development of a protein-based biosensing system.  Regulatory proteins 
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are typically quite specific to their effector molecule.  Regulatory proteins, in both 
positively and negatively regulated systems, typically undergo significant 
conformational changes upon binding their effector molecules.  Through the 
strategies described previously, these conformational changes can be followed 
when coupled with either a reporter protein fusion in a genetically-encoded 
strategy, or a site-specifically attached fluorophore in a chemically-modified 
approach.  In either case, the resulting conformational change results in a 
change in fluorescence signal intensity which can be correlated to the 
concentration of the effector/analyte molecule.  In one such system, the protein 
MerR, which binds specifically to Hg2+ has been engineered such that upon 
binding, a change in fluorescence is observed.[99]  Another example of a 
regulatory protein-based sensing system is the detection of cGMP by fusing the 
regulatory element of various cGMP protein kinases to variants of GFP.[100] 
 
CONCLUSIONS AND FUTURE POTENTIAL 
 Continued work in the fields of cell-and protein-based biosensors should 
contribute to further exploitation and enhancement of the unique advantages that 
they offer in the detection of a variety of analytes in different types of samples 
using diverse analytical platforms.  Cell-based biosensing systems are most 
promising in their applicability to the development of rugged biosensing systems 
which give some degree of bioavailability information on the target analyte.  The 
ruggedness of cell-based systems will only increase with the further development 
of spore-based biosensing systems, which is a growing field.  Protein-based 
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sensing systems, due to their rapid assay times, are the best candidate for the 
development of real-time monitoring devices which are especially useful in 
therapeutic and biomedical devices.   
 The identification of additional regulatory proteins, receptors, enzymes, 
etc. should expand the ranks of chemical species that can be detected.  
Moreover, the identification, characterization, and alteration of new light-emitting 
bioreporters should lead to advanced, multiplexed assays capable of measuring 
several analytes simultaneously.  Advancements in optical instrumentation and 
miniaturization should, undoubtedly, yield smaller, more rugged, less expensive 
methods along with the selectivity and sensitivity afforded by these genetically 
engineered cells.  Miniaturization to array-based or microfluidic chip-based 
platforms reduces volumes of reagents and samples as well as wastes produced.  
There is no doubt that the future is bright for cell- and protein-based 
bioluminescent biosensors as they will find further application in the fields of 
environmental monitoring, toxicology, pharmacology, drug-screening, and 
medical/clinical applications. 
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STATEMENT OF RESEARCH 
 The underlying theme of the work presented here is to engineer bacterial 
cells and proteins to improve their response characteristics such that they can be 
integrated into biosensing systems.  Nature has devoted billions of years to 
evolving the diversity of biological functionalities, which is evident in the variety of 
organisms that today inhabit all of the environments of Earth ranging from 
rainforests to water reservoirs beneath the South Pole to volcanic vents on the 
ocean floor to boiling hot, acidic mineral springs.  Biological moieties (i.e., 
proteins, enzymes, tissues, and whole cells) have developed mechanisms to 
detect and respond to very specific chemical species in complex mixtures as well 
as tolerate and thrive in harsh living environments.  Here, we aim to take 
advantage of the exceptional inherent selectivity, sensitivity, and stability that 
exists throughout the natural world in the development of analytical systems to 
address challenges regarding the detection of both environmentally- and 
physiologically-relevant small molecules.  The work presented in this dissertation 
was guided by the following hypotheses: 
 Regulatory genetic circuits from a microorganism that respond to a 
specific small molecule effector can be exploited by replacing the genes 
regulated in the native organism with an appropriate reporter gene, thus 
allowing detection and quantification of the effector molecule to which the 
regulatory system responds to. 
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 By isolating and rationally engineering appropriate protein (i.e., hinge-
motion periplasmic chemotaxis proteins and regulatory proteins) that 
serve as the biorecognition element in a biosensing system, we can attain 
the required selectivity and sensitivity needed to detect small molecules of 
interest in complex sample matrices. 
 Utilizing a protein from a hyperthermophile, Thermotoga maritima, we can 
develop a protein-based sensing system with remarkable thermal stability.  
This increased stability results in a sensing system that is rugged enough 
to operate at physiological temperatures for extended periods of time.  
Additionally, the improved stability makes this sensing system amenable 
to storage and transport in extreme environments. 
 The work presented here describes research that sets out to explore the 
hypotheses set forth above.  Biosensing systems have been developed based 
upon both intact living cells, as well as isolated regulatory and binding proteins.  
Through each of these projects, we set out to maintain the desirable 
characteristics inherent in the native biological moieties while rationally 
engineering them as appropriate to tailor other characteristics (i.e., binding 
affinity, thermal stability, and selectivity) when appropriate.  Below is a brief 
description of the chapters to follow: 
 Chapter two describes the development of a whole-cell sensing system for 
the detection of hydroxylated polychlorinated biphenyls (OH-PCBs).  The 
regulatory protein (HbpR) and promoter (PhbpCAD) from the organism 
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Pseudomonas azelaica were engineered to regulate the expression of the 
bioluminescent reporter protein, bacterial luciferase (LuxAB).  The result is 
a bacterial cell that produces bioluminescence whose intensity can be 
correlated to the concentration of OH-PCBs that are present in 
environmental or biological samples. 
 Chapter three details the development of a protein-based sensing system 
based upon the aforementioned HbpR regulatory protein.  This protein 
undergoes a drastic conformational change upon effector molecule 
binding.  By labeling the native cysteines present in the protein with an 
environmentally-sensitive fluorophore, we were able to observe a 
concentration-dependent change in fluorescence in response to the 
concentration of OH-PCBs present. 
 In chapter four, the development of a protein-based sensing system for 
glucose based upon the periplasmic glucose bindign protein (GBP) from 
E. coli is described.  Protein-based sensing systems using GBP labeled 
with an environmentally-sensitive fluorophore have been previously 
developed with binding affinities in the micromolar range.  In order to shift 
the binding affinity into the physiologically-relevant millimolar range, 
truncated fragments of native GBP (tGRPs) were designed and 
characterized. 
 The design and characterization of a protein-based sensing system for 
glucose based upon GBP from the hyperthermophile Thermotoga 
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maritima is described in chapter five.  The biosensing system presented 
here differs from those presented in the previous chapters, in that the 
source of fluorescence measured is the protein’s intrinsic tryptophan 
fluorescence.  This eliminates the need for an extra chemical labeling 
step.  Additionally, by employing a binding protein from a 
hyperthermophile, exceptional thermal stability has been observed, 
resulting in a remarkably rugged biosensing system.   
 
 
 
 
 
 
 
 
 
 
Copyright © Kendrick Bruce Turner 2011 
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CHAPTER TWO 
HYDROXYLATED POLYCHLORINATED BIPHENYLS DETECTION BASED 
ON A GENETICALLY ENGINEERED BIOLUMINESCENT WHOLE-CELL  
SENSING SYSTEM 
Chapter reprinted from Turner, et al.; Analytical Chemistry, 2007, 79, 5740-5745, 
by permission of American Chemical Society, copyright (2007). 
  
INTRODUCTION 
 Since the 1970s, the apparent toxicities of polychlorinated biphenyls 
(PCBs) have been scrutinized in much detail.  PCBs have been shown in 
numerous studies to contribute to negative health effects[101-104] and to be 
persistent in biological and environmental samples.[105]  Hydroxylated PCBs 
(OH-PCBs) have also been more closely examined as potentially exhibiting 
significant toxic health effects.  OH-PCBs have been detected in the environment 
at concentrations as much as 3.5 times that of PCBs, possibly originating from 
sewage treatment plants and byproducts of industrial-scale reactions involving 
biphenyl and biphenylol.[106]  Additionally, OH-PCBs are also present in 
biological fluids as metabolites of PCBs.[105]  Many OH-PCBs have been 
identified in human serum samples and may be present at concentrations 
comparable to the parent PCBs.[101]  It has been shown that some OH-PCBs 
have estrogenic and antiestrogenic activities in various mammalian models,[101-
104] inhibit gap junctional intercellular communication,[103] activate aryl 
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hydocarbon receptors,[103] and form DNA adducts leading to damage of 
DNA.[107] 
 Due to the toxicity and environmental and biological persistence of OH-
PCBs, it is necessary to have efficient and economical methods to detect and 
quantify them.  Currently, the methods of choice are GC-MS and LC-MS.[108]  
These methods have excellent detection limits and can effectively identify and 
quantify OH-PCBs.  However, sample extraction, cleanup and derivatization 
steps are required for analysis.  These factors combined with the expenses 
associated with instrumentation and the need for trained laboratory technicians 
quickly drives up the cost and time required for analysis. 
 Alternatively, whole-cell sensing systems provide several advantages over 
traditional techniques.  Most notably, the speed of analysis is increased due to 
the lack of need for extensive sample preparation steps and the ability to 
evaluate multiple samples in one analytical run.  Whole-cell sensors, due to the 
inherent selectivity of the recognition/regulatory proteins involved, can be used in 
complex sample matrices without significant impact from interferants.  In addition, 
a whole-cell sensing system could be developed into a field-portable assay and 
used as an on-site screening tool for both environmental and biological samples, 
allowing for a more effective selection of samples to be evaluated in more detail.  
Lastly, information on bioavailability of analytes is obtained with whole-cell 
sensing systems, which facilitates the prediction of fate and effect of the 
pollutants for toxicological studies.  
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 A common strategy in the development of a whole-cell sensing system is 
placing a gene which encodes for a reporter protein under the control of a 
specific recognition element, such as a regulatory protein, for the analyte of 
interest as shown in Figure 2.1.  Biosensors of this type have been developed for 
a variety of analytes.  More in-depth information and examples can be found in a 
number of reviews.[109-111]  Specifically, we have developed a whole-cell 
sensing system for the detection of OH-PCBs by employing the strain 
Pseudomonas azelaica HBP1.  This bacterium contains the hbpCAD genes, 
which are responsible for the degradation of hydroxylated biphenyls.  The 
expression of these genes is negatively regulated by a regulatory protein 
encoded by the gene hbpR located upstream from the hbpCAD genes.  A strain 
of Escherichia coli carrying a recombinant plasmid consisting of the luxAB 
reporter gene, coding for bacterial luciferase, under control of the HbpR 
regulatory protein was constructed[112] and employed as a whole-cell sensing 
system in the present study.  In the presence of analytes, such as OH-PCBs, the 
regulatory protein HbpR activates transcription through the hbp promoter 
resulting in the expression of the reporter gene.  This expression can then be 
monitored by measuring bioluminescence emission after addition of decanal, a 
substrate for luciferase.  Within a certain range of analyte concentrations, the 
expression of the reporter gene is dose-dependent, therefore, the intensity of the 
analytical signal is directly related to the amount of target compound.   
 Analyzing the concentration of OH-PCBs in serum samples as a 
biomarker of PCB exposure is essential for toxicological studies and remediation  
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purposes.  The hydrophilic nature of the hydroxyl group in OH-PCBs suggests 
that these chemicals may be readily excreted from the body.  However, the most 
predominant PCB metabolites found in biological fluids contain between five to 
seven chlorines with one hydroxyl group in the biphenyl ring.[113, 114]  
Therefore, the possibility of retention rather than excretion also exists due to the 
increased hydrophobicity contributed by physicochemical properties of chlorines 
attached to the biphenyl backbone.  Moreover, their high lipophilicity and affinity 
to certain proteins such as the thyroxin-transporting protein, transthyretin (TTR) 
lead to the retention of OH-PCBs in different body compartments, mainly in 
blood.[115]  
 In this study, we have employed a genetically engineered bacterium to 
develop a whole-cell sensing system to detect the presence of a variety of OH-
PCBs in both environmental and biological samples.  This sensing system has 
been optimized with respect to important assay conditions, and the feasibility of 
the application of this system as a screening tool has been discussed.  
 
MATERIALS AND METHODS 
Chemicals and media 
 2-Hydroxybiphenyl was obtained from Sigma-Aldrich Corp. (St. Louis, 
MO). In Table 2.1, OH-PCBs No 2, 5, 6, and 8-12 were obtained from 
Accustandard Inc. (New Haven, CT), OH-PCBs No 3 and 4 were obtained from  
53 
 
Table 2.1.  Response of the whole-cell sensing system to various OH-PCBs.  
No Compound log (A/Ao)
a - log ED50
b Detection 
Limit (M)c 
1 2-Hydroxy-4’-chlorobiphenyl 0.44 1.76 ± 0.37 1.0×10-6 
2 2-Hydroxy-3’4’-dichlorobiphenyl 0.88 5.66 ± 0.07 5.0×10-7 
3 2-Hydroxy-3,5-dichlorobiphenyl 0.50 2.09 ± 0.24 5.0×10-5 
4 2-Hydroxy-2’,3,5’-trichlorobiphenyl 0.56 3.86 ± 0.25 1.0×10-5 
5 2-Hydroxy-2’,4’,6’-trichlorobiphenyl 0.37 3.21 ± 0.06 1.0×10-8 
6 2-Hydroxy-2’,5,5’-trichlorobiphenyl 0.49 4.17 ±0.03 5.0×10-6 
7 2-Hydroxy-3’,4’,5-trichlorobiphenyl 0.24 4.84 ± 0.15 1.0×10-9 
8 2-Hydroxy-3’,5,5’-trichlorobiphenyl 0.22 5.16 ± 0.32 1.0×10-7 
9 2-Hydroxy-2’,3’,4’,5’-tetrachlorobiphenyl 0.47 3.21 ±0.06 5.0×10-5 
10 2-Hydroxy-2’,3’,5’,6’-tetrachlorobiphenyl 0.48 4.47 ± 0.11 5.0×10-6 
11 2-Hydroxy-2’,4’,5,6’-tetrachlorobiphenyl 0.20 3.36 ± 0.62 1.0×10-6 
12 2-Hydroxy-2’,3’,4’,5,5’-pentachlorobiphenyl 0.35 4.35 ± 0.76 1.0×10-6 
13 3-Hydroxy-4’-chlorobiphenyl 0.46 2.29 ±0.24 1.0×10-7 
14 4-Hydroxy-4’-chlorobiphenyl 0.31 2.87 ± 0.19 5.0×10-5 
15 4-Hydroxy-2’,3-dichlorobiphenyl 0.75 4.43 ±0.09 1.0×10-8 
16 4-Hydroxy-2’,5’-dichlorobiphenyl 0.61 3.46 ± 0.07 1.0×10-7 
17 4-Hydroxy-3,3’-dichlorobiphenyl 0.64 4.58 ± 0.14 1.0×10-8 
18 4-Hydroxy-3,4’-dichlorobiphenyl 0.60 3.75 ± 0.05 1.0×10-6 
19 4-Hydroxy-3’,4’-dichlorobiphenyl 0.41 3.49 ± 0.69 1.0×10-8 
20 4-Hydroxy-3,5-dichlorobiphenyl 0.63 3.49 ± 0.05 5.0×10-7 
21 4-Hydroxy-2’,3,5-trichlorobiphenyl 0.32 3.75 ± 0.05 1.0×10-6 
22 4-Hydroxy-3,3’,4’-trichlorobiphenyl 0.82 4.79 ± 0.05 1.0×10-7 
23 4-Hydroxy-3,3’,5-trichlorobiphenyl 0.42 2.49 ± 0.11 1.0×10-6 
24 4-Hydroxy-3,3’,5’-trichlorobiphenyl 0.50 4.21 ±0.06 1.0×10-6 
25 4-Hydroxy-3,4’,5-trichlorobiphenyl 0.38 3.40 ± 0.14 1.0×10-6 
26 4-Hydroxy-3,3’,4’,5-tetrachlorobiphenyl 0.21 3.49 ± 0.30 1.0×10-5
27 4-Hydroxy-2’,3,4’,5-tetrachlorobiphenyl 0.12 4.42 ± 0.26 1.0×10-7 
 
a The response ratio (A/Ao) was calculated by dividing the maximum bioluminescence signals for 
each hydroxylated PCB (A) by the bioluminescence signals for the blank (Ao) 
b ED50 was defined as concentration at 50% maximum induction, and was calculated by using 
GraphPad Prism 4.0 software.  
c Detection limit was defined as the analyte concentration that corresponds to a signal-to-noise 
ratio of 3.  
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Ultra Scientific Inc. (North Kingstown, RI), and OH-PCBs No 1, 7, and 13-27 
were kind gifts from Hans Lehmler at the University of Iowa.  The purities (≥  
95.0%) of these synthesized OH-PCBs were verified by Agilent GC-MS 5975 
prior to experiments.  
 Dimethyl sulfoxide (DMSO, ≥ 99.9%, for molecular biology), n-decanal (≥ 
99%, for GC, liquid), ethanol (anhydrous, ≥ 99.5%, 200 proof), glycerin (meets 
USP testing specifications), and human serum (from clotted human male whole 
blood, sterile-filtered, mycoplasma tested, virus tested) were obtained from 
Sigma-Aldrich Corp. (St. Louis, MO).  Deionized distilled water was produced by 
a Milli-Q water purification system (Millipore, Bedford, MA). 
 Escherichia coli strains were grown at 37 oC on Luria-Bertani (LB) medium 
(BIO 101, Vista, CA) containing ampicillin (100 µg/mL, Sigma-Aldrich Corp., St. 
Louis, MO).  For the luciferase induction assay, mineral medium (MM) defined by 
Gerhardt et al.,[116] was prepared and supplemented with 0.01% tryptone, 
0.005% yeast extract, and 10 mM D-(+)-glucose before use, as described by 
Jaspers et al. [112]  MM (per liter) was prepared from the ingredients: 1.00 g of 
NH4Cl, 3.49 g of Na2HPO4·2H2O, 2.77 g of KH2PO4, 20 mL of Hunter’s vitamin-
free mineral base, and 2.0 mL of a vitamin solution, adjusted to pH 6.8.  Hunter’s 
vitamin-free mineral base contained (per liter): 10 g of nitrilotriacetic acid 
(neutralize with 6.00 g of KOH), 14.5 g of MgSO4·7H2O, 3.33 g of CaCl2·2H2O, 
9.74 mg of (NH4)6Mo7O24·4H2O, 99 mg of FeSO4·7H2O, and 50 mL of the Metals 
44 solution.  The composition of Metals 44 (per 100 mL) was as follows: 387 mg 
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of Na4EDTA·4H2O, 1.10 g of ZnSO4·7H2O, 914 mg of FeSO4·7H2O, 154 mg of 
MnSO4·H2O, 39.2 mg of CuSO4·5H2O, 24.8 mg of Co(NO3)2·6H2O, 17.7 mg of 
Na2B4O7·19H2O, and was neutralized with H2SO4. The vitamin solution (per 100 
mL) was prepared by mixing 0.50 mg of biotin, 50 mg of nicotinic acid, and 25 mg 
of thiamine hydrochloride.  MM was sterilized and stored at 4 oC before use.  All 
chemicals for MM preparation were purchased from Sigma-Aldrich Corp. (St. 
Louis, MO), and were at least cell culture tested grade. 
 
Preparation of E. coli cells harboring plasmid pHYBP109 
 Cells were obtained as a frozen glycerol stock.  A stab was taken from this 
stock and grown overnight at 37 °C in a culture tube containing 2 mL of LB 
medium and ampicillin (100 µg/mL).  The following day, the 2 mL culture was 
transferred to a 1 L flask containing 250 mL of LB medium and grown at 37 °C to 
an optical density at 600 nm (OD600) of approximately 0.90.  The cells were then 
dispensed into 1.5 mL microcentrifuge tubes in 1 mL aliquots and stored at -80 
°C until use.  A volume of 50 µl of sterilized glycerin was added to each 1 mL 
stock of cells for preservation purposes.  Unless otherwise specified, all the cells 
were grown in a rotary shaker at 200 rpm. 
 
Detection of compounds in dimethyl sulfoxide 
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 Stock solutions of each compound were prepared at a concentration of 1 x 
10-2 M by dissolving the appropriate mass of each compound in 1.0 mL of DMSO 
in a microcentrifuge tube and vortexing until dissolved.  From these, solutions in 
a concentration range of 5.0×10-3 - 1.0×10-9 M were prepared by serial dilution of 
the original stock solution in DMSO.  In addition, a blank was prepared containing 
only DMSO.  Each set of solutions was prepared fresh and the 1 x 10-2 M stock 
solutions were saved and frozen at -20 °C after use. 
 Immediately prior to use in each assay, a microcentrifuge tube containing 
a 1 mL aliquot of cells was removed from the -80 °C freezer and placed in a room 
temperature water bath for 2 minutes, and then on ice.  For the final assay 
solution, 1.9 mL of MM, 33 µL of thawed cell suspension, and 20 µL of a 
compound at each concentration along with a blank as prepared above were 
dispensed into a series of 14 mL culture tubes in triplicate.  These tubes were 
placed at 30 °C on an orbital shaker at 225rpm for a 4 hour incubation period.   
 Following incubation, a volume of 200 µL of the cell suspension from each 
culture tube was dispensed into the wells of a 96-well microtiter plate in triplicate.  
A volume of 100 µL of stock n-decanal substrate solution (2 mM in 1:1 
ethanol/H2O) was added into the reaction assay by automated injection for the 
bioluminescence signal measurement.  Light output was integrated from 5 s to 15 
s after n-decanal injection for each of the wells in the plate using a POLARstar 
OPTIMA luminometer (BMG Labtech, Offenburg, Germany).  The total light 
signal was expressed as relative light units (RLU). 
57 
 
For experimental optimization, the general protocol described above was 
employed, unless otherwise specified in the text.  All assays were conducted in 
triplicate. 
 
Detection of model compound in human serum 
 2-Hydroxy-3’,4’-dichlorobiphenyl was used to evaluate the assay in human 
serum.  This compound was prepared as above in a concentration range from 1 
x 10-2 M – 1 x 10-8 M in DMSO along with a blank containing only DMSO.  In a 
separate set of microcentrifuge tubes, 10 µL of each of these solutions was 
dispensed into 90 µL of human serum.  This resulted in serum samples with the 
compound of interest present in a range of 1 x 10-3 M – 1 x 10-9 M along with a 
blank.  Additionally, a set of samples was prepared using deionized water instead 
of human serum as a comparison.  These solutions were then used to complete 
the assay as described above. 
 
Detection of a compound mixture in human serum 
 A mixture of the following 10 OH-PCBs was prepared at a concentration of 
1 x 10-3 M with respect to each individual compound in DMSO:  2-hydroxy-3’,4’-
dichlorobiphenyl, 4-hydroxy-3,3’,4’-trichlorobiphenyl, 2-hydroxy-3’,4’,5-
trichlorobiphenyl, 2-hydroxy-3’,5,5’-trichlorobiphenyl, 3-hydroxy-4’-chlorobiphenyl, 
4-hydroxy-2’,3,4’,5-tetrachlorobiphenyl, 4-hydroxy-2’,5’-dichlorobiphenyl, 4-
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hydroxy-3’,4’-dichlorobiphenyl, 4-hydroxy-3,3’-dichlorobiphenyl, 4-hydroxy-2’,3-
dichlorobiphenyl.  To prepare this solution, 10 µL of the 1.0 × 10-2 M stock 
solution of each compound was dispensed into a single microcentrifuge tube.  
Serial dilutions were made using this solution to create a mixture in DMSO in a 
concentration range of 1 x 10-3 – 1 x 10-8 M with respect to each compound and a 
concentration of 1 x 10-2 M – 1 x 10-7 M with respect to total OH-PCBs.  In a 
separate set of microcentrifuge tubes, 10 µL of each of these solutions was 
dispensed into 90 µL of human serum, yielding samples of the mixture in human 
serum in a concentration range of 1 x 10-4 – 1 x 10-9 M with respect to each 
compound.  These samples were then used to complete the assay as described 
above. 
 
Statistical analysis 
 The results presented are the averages of the values obtained in three 
independent experiments.  GraphPad Prism 4.0 (GraphPad Software Inc., San 
Diego, CA) was used to generate non-linear best-fit lines of the data.  
 
RESULTS AND DISCUSSION 
 The strain Pseudomonas azelaica HBP1 is able to use hydroxylated 
biphenyls as sole carbon and energy sources.  The mechanism for the 
degradation of 2-hydroxybiphenyl by P. azelaica HBP1 has been well 
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characterized.[117]  The metabolism involves three enzymes encoded by the 
hbpCAD genes, which are negatively regulated by the HbpR protein.  To study 
the PhbpC promoter activity of P. azelaica HBP1, a plasmid (designated as 
pHYBP109) containing hbpR-PhbpC-luxAB fusion was constructed and 
transformed to E. coli by Jaspers et al.[112] Induction experiments were carried 
out using 2-hydroxybiphenyl.  Increasing bioluminescence signals upon induction 
with 0.2 mM of 2-hydroxybiphenyl for increasing induction times suggested the 
direct activation of PhbpC promoter by the compound binding to the HbpR 
protein.[112]  In our laboratory, initial experiments were conducted by treating 
these recombinant E. coli cells with varying concentrations of 2-hydroxybiphenyl.  
A preliminary detection limit of 1 x 10-6 M could be obtained (data not shown), 
under the experimental conditions reported by Jaspers et al.[112]  The detection 
limit is defined as the minimum analyte concentration that corresponds to a 
signal-to-noise ratio of 3.   
 A whole-cell sensing system is a genetically modified system constructed 
in such a way that in the presence of an analyte, expression of a reporter protein 
is triggered.  In the plasmid used in this study, hbpR, the gene encoding for the 
HbpR protein, is positioned upstream from the luxAB genes, which code for the 
bioluminescent reporter protein, luciferase.  In this way, the expression of 
luciferase is placed under the control of the PhbpC promoter, which is regulated by 
the HbpR protein.  Thus, the expression of luciferase in E. coli harboring 
pHYBP109 is mediated by the HbpR regulatory protein from the same regulatory 
circuit.  In the absence of hydroxylated biphenyls, the HbpR protein binds to the 
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promoter and prevents the expression of luxAB genes.  In the presence of 
hydroxylated biphenyls, the HbpR protein undergoes a conformational change 
upon binding of the inducer molecules, causing release of the protein-inducer 
complex from the promoter.  As a result, expression of the reporter protein 
occurs.  
 In a study carried out by Jaspers et al. to evaluate the selectivity of the 
HbpR protein, a group of chemicals such as biphenylic compounds, polycyclic 
aromatic hydrocarbons, and monoaromatic hydrocarbons, among others, were 
screened using engineered bacteria.[112] It was found that only a few structurally 
similar chemicals containing the biphenyl backbone showed significant activity.  
In fact, when the signals were normalized to the response to 2-hydroxybiphenyl 
at a concentration of 2 mM, relative luciferase activities more than 32% were 
observed for only a narrow range of compounds.  Additionally, some chemicals 
showing activity had a hydroxyl group at the ortho biphenyl ring position.  On the 
other hand, biphenyl, chlorobiphenyl, or compounds with a monoaromatic 
structure failed to show activity.  Because of the selectivity of the HbpR protein in 
recognizing compounds with biphenyl backbone and a hydroxyl group, we 
envisioned that employing engineered E. coli harboring plasmid pHYBP109 as a 
whole-cell sensing system would permit us to detect a group of structurally 
similar OH-PCBs.  Moreover, the broad inducer range of TbuT[118] and 
XylR[119], which belong to the same NtRC family of proteins as HbpR, further 
supported the investigation of the inducer spectrum of HbpR protein by exposing 
the recombinant cells to OH-PCBs.  As a pioneer study, cells were exposed to 
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five randomly selected OH-PCBs.  Significant increase of the bioluminescence 
signal as compared to a blank was observed for all five compounds tested.  The 
maximum signal ratio of 1.72 ± 0.11 (mean ± standard deviation; n=3) was found 
by using 2-hydroxy-3’,4’-dichlorobiphenyl at a concentration of 1 x 10-3 M after 2h 
incubation period.  Thus, this chemical was used as a model compound for 
further optimization of assay parameters.   
 Because only the regulator and promoter region of the hbp operon was 
inserted into the luciferase expression vector, the degradation of OH-PCBs by 
the cells is unlikely.  For this reason, the toxicity of OH-PCBs to the bacteria used 
in our assay was evaluated.  Cell growth was monitored with/without the addition 
of 2-hydroxy-3’,4’-dichlorobiphenyl, at a final concentration of 1 x 10-5 M,  to the 
medium containing cells harboring the pHYBP109 plasmid.  Optical densities at 
600 nm (OD600) were checked every hour for 8 hours.  Observed differences in 
OD600 of less than 10% between the two cell growth curves indicate that the 
toxicity of the compound is negligible at the tested concentration. 
 Important assay parameters were optimized in order to improve the overall 
performance of the biosensing system.  Among these were the growth stage at 
which the cells were harvested, the storage method of the harvested cells, and 
the length and temperature of the incubation of the cells with the analytes.  The 
optimum biosensing conditions were found to be harvesting cells at an optical 
density of approximately 0.9 measured at 600 nm, storage of the cells at -80 ºC 
until use, and incubating the cells at 30 ºC for 4 h during the assay.    
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  Once all biosensing system parameters were optimized, the genetically 
engineered whole cells were exposed to varying concentrations of 2-hydroxy-
3’,4’-dichlorobiphenyl.  An increase in the bioluminescence signal was observed 
with increasing concentration of the compound as shown in Figure 2.2.  Data  
points were fitted with a sigmoidal dose-response curve, and a correlation 
coefficient R2 of 0.9977 was obtained.  The detection limit falls in the order of 10-8 
M.  When the analyte concentration was in the range of 1 x 10-7 M to 1 x 10-3 M, 
a rapid increase of the bioluminescence signal was observed.  Concentrations of 
the model compound higher than 1 x 10-3 M caused the bioluminescence signal 
to decrease significantly (data not shown).  This observation is in agreement with 
the data published by Hay et al. for the detection of 2,4-dichlorophenol using a 
bioluminescent whole-cell reporter.[120]  It is speculated that at higher 
concentrations of the analyte, there is a toxic effect, which leads to a reduced 
number of living cells and a subsequent significant decrease in the response. 
 The next step in our research aimed at evaluating the response of the 
whole-cell sensor to a variety of OH-PCBs.  However, it is difficult to assess the 
most predominant OH-PCBs in human serum[104] because of the unavailability 
of these compounds for use as standards from commercial sources.  For that, a 
range of 27 commercially available OH-PCBs at various concentrations were 
tested.  A dose-dependent response was observed for all of these compounds.  
A representative example for 4-hydroxy-3,3’,4’-trichlorobiphenyl is reported in 
Figure 2.2.  The data from each analyte was fit with a sigmoidal dose-response 
curve, and parameters such as log ED50 and log (A/Ao) were calculated and 
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Figure 2.2.  Dose-response curves of the whole-cell sensing system.  The 
curves were obtained with 2-hydroxy-3’,4’-dichlorobiphenyl (■) and 4-hydroxy-
3,3’,4’-trichlorobiphenyl (▼) under optimized experimental conditions.  The 
bioluminescence signals have been corrected with respect to the blank.  Values 
represent the means ± standard deviation of triplicate determinations. 
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summarized in Table 1.  ED50 was defined as the concentration at 50% of 
maximum induction, and was calculated by using GraphPad Prism 4.0 software.  
The induction ratio (A/Ao) was calculated by dividing the maximum 
bioluminescence signal for each hydroxylated PCB (A) by the bioluminescence 
signal for the blank (Ao).  The maximum induction levels and the concentrations 
to achieve the maximum induction varied among the analytes tested.  The 
dynamic range for the detection of hydroxylated PCBs covered two to five orders 
of magnitude.  The detection limits ranged from 1 x 10-9 to 1 x 10-5 M.  These 
results are in agreement with previous studies which demonstrate differential 
light responses in whole-cell sensing systems to various members of a class of 
related compounds.[121, 122]  An attempt to explain the differences in the 
responses to the chemicals, based on their molecular structure, is ongoing at this 
stage. 
 In order to validate the response of this luciferase-based whole-cell 
sensing system to the PCB metabolites in a biological matrix, human serum was 
spiked with a range of concentrations of the model compound.  The assay was 
carried out under the optimized experimental conditions.  As shown in Figure 2.3, 
a dose-response curve was obtained with a log ED50 of -5.29, and a detection 
limit of 5.0 × 10-8 M.  Increased bioluminescence signals were observed for the 
serum samples spiked with 2-hydroxy-3’,4’-dichlorobiphenyl, as compared to the 
signals produced by the same analyte concentrations in the absence of the 
biological matrix.  It is believed that this increased signal is due to the presence 
of proteins found in serum.  These proteins may prevent the analyte from  
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Figure 2.3.  Dose-response curves of the whole-cell sensing system in 
serum.  The curves were obtained with 2-hydroxy-3’,4’-dichlorobiphenyl in 90% 
water/10% DMSO (■) or 90% serum/10% DMSO (▼).  The bioluminescence 
signals have been corrected with respect to the blank.  Values represent the 
means ± standard deviation of triplicate determinations.  
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interacting with the walls of the plastic tube, thus making the analyte more 
available for diffusion into the cells.  Overall, the resultant bioluminescence 
response of the whole-cell sensing system to the model compound in serum 
demonstrates the feasibility of direct detection of OH-PCBs in serum samples.  
 In real samples, PCB metabolites are present as mixtures. Various 
contamination patterns of hydroxylated PCBs have been reported in the literature 
for fish plasma [123], polar bear whole blood,[124] and human whole blood,[125] 
plasma,[126-129] serum[114, 130] and cerebrospinal fluid samples[108].  
Additionally, the ratios of total OH-PCBs to total PCBs calculated were around 4-
56 % in human plasma[126] or even found to be 4-8 times higher in the whole 
blood of polar bears[124].  In our laboratory, the responses of the whole-cell 
sensing system to a model mixture of 10 OH-PCBs were tested.  The obtained 
dose-response curve with a detection limit of 5.0 × 10-8 M suggests the potential 
for employing this sensing system as a screening method for multiple OH-PCBs 
contaminated samples.  Notably, the application of this whole-cell sensing 
system to the detection of OH-PCBs in biological and environmental samples 
could remarkably reduce the analysis time and cost posed by currently used 
conventional methods, such as GC or LC methods.  Further studies utilizing this 
whole-cell sensing system will enable us to monitor the bioavailable PCB 
metabolites in large pools of environmental and biological samples. This will 
provide a new insight into the pollution status at certain sites for better 
understanding of the current ecological conditions of the living environment.  
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CONCLUSIONS 
 In this work, a rapid and sensitive sensing system for the detection of 
hydroxylated PCBs based on genetically engineered whole cells has been 
developed.  Additionally, the performance of this whole-cell sensing system has 
been demonstrated in a biological sample matrix.  The results achieved suggest 
that the sensing system may find applications in biomedical analysis as well as in 
the environmental monitoring of hydroxylated PCBs.  The ruggedness of the 
proposed sensing system can be further improved by employing lyophilized cells, 
which can be easily stored and transported to the field, and reconstituted for later 
use.  Upon miniaturization and integration into an appropriate assay platform, we 
envision this system being developed into a rapid, high-throughput, field-portable 
method for the detection of hydroxylated PCBs in both environmental and 
biological samples. 
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CHAPTER THREE 
ENGINEERING THE TRANSCRIPTIONAL REGULATORY PROTEIN, HbpR, 
TO DEVELOP A SCREENING METHOD FOR HYDROXYLATED 
POLYCHLORINATED BIPHENYLS 
 
INTRODUCTION 
Polychlorinated biphenyls (PCBs) are a class of 209 congeners of 
persistent, toxic organochlorine compounds that have been exhaustively shown 
to contribute to a variety of negative health outcomes in humans.  Specifically, 
PCBs have been shown to affect neurological and cognitive development,[131, 
132] increase the risk of childhood leukemia,[133] reduce the success of in vitro 
fertilization attempts,[134] and cause endocrine system disruption.[135, 136]  
These compounds are nearly ubiquitous in the environment, as well as present in 
some homes and buildings due to their many years of use in applications such as 
plasticizers, surface coatings, inks, adhesives, flame retardants, duplicating 
paper, wire insulators, caulking materials, elastic sealants, heat insulation, and 
electrical transformers.[137]  PCBs are classified as persistent organic 
compounds, meaning that once present in the environment they are not easily 
degraded by natural physical, chemical or biological processes. Additionally, 
PCBs are not readily eliminated from most complex organisms and exhibit a high 
degree of lipophilicity.  As a result, there is a bioaccumulation effect for PCBs 
and an increase in exposure throughout the food chain (biomagnification) and 
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susceptibility of humans to exposure both from the environment and from dietary 
sources. 
Upon human exposure to PCBs, hydroxylated metabolites are formed in 
vivo by cytochrome p450 enzymes.[138]  The resulting hydroxylated PCBs (OH-
PCBs) are less lipophilic, thus resulting in a decreased half-life in the body from 
an estimated median value of 37 years[139] to a half-life on the order of 
days.[140]  Studies have shown that OH-PCBs may possess unique toxicity, 
acting as endocrine disruptors,[141] increasing the formation of reactive oxygen 
species,[142] and disrupting the membrane potential of neocortical cells.[143]  
While OH-PCBs as a class have a relatively short biological half-life, some 
congeners, particularly those derived from highly chlorinated parent PCBs, are 
not easily eliminated from the body.[144]  The shortened half-life and increased 
hydrophilicity of OH-PCBs contribute to a lower total concentration in body fluids 
and tissues when compared to their parent PCBs.  Typically, the total OH-PCB 
concentration is approximately an order of magnitude lower than the total PCB 
concentration when measured in serum.[140]  Since the serum concentration of 
OH-PCBs corresponds to that of PCBs, OH-PCBs can serve as a biomarker for 
PCB exposure. 
Previously, we have developed a whole-cell biosensing system for OH-
PCBs employing the regulatory protein HbpR from Pseudomonas azelaica.[4]  
HbpR  is a member of the XylR/DmpR subfamily of σ54-dependent regulatory 
proteins (figure 3.1).[145]  Acting as a negative genetic regulator, HbpR 
undergoes a conformational change, releases from the operator region, and  
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allows transcription of genes under the control of the corresponding promoter 
upon effector binding.  We hypothesize that we can exploit this conformational 
change in the development of a protein-based biosensing system for the 
detection of OH-PCBs.  By covalently attaching an environmentally-sensitive 
fluorescent molecule to cysteines in HbpR, the fluorescent signal may change in 
a dose-dependent manner upon OH-PCB binding.   
Protein-based sensing systems have the distinct advantage of typically 
producing a sample-to-answer response much faster than cell-based sensing 
systems.  Previous work with HbpR suggests that the protein binds to most OH-
PCBs, albeit with different affinities.[4]  As a result of this class-specificity and the 
relatively fast assay times associated with protein-based sensing systems, we 
believe that a biosensing system based on HbpR is well-suited for the 
development of a screening method for large numbers of samples to select 
positive samples for more labor-intensive and time-consuming analysis by 
traditional methods, such as, gas chromatography/mass spectrometry.  In this 
work, we describe the protein engineering and fluorescent labeling of HbpR, and 
the investigation of its response to OH-PCBs in buffer as well as in spiked human 
serum. 
 
EXPERIMENTAL 
Reagents.  Custom oligonucleotide primers were purchased from Operon 
Biotechnologies (Huntsville, AL).  BamHI, EcoRI, HindIII, T4 DNA ligase, and Pfu 
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DNA polymerase were purchased from Promega (Madison, WI).  Luria-Bertani 
(LB) broth and agar, 2-amino-2-hydroxymethyl-propane-1,3-diol hydrochloride 
(Tris-HCl), sodium chloride, tris(2-carboxyethyl)phosphine and 
ethylenediaminetetraacetic acid (EDTA) were purchased from Fisher Scientific 
(Fair Lawn, NJ).  OH-PCB reference standards for the compounds listed in table 
3.1 were purchased from AccuStandard (New Haven, CT).  Ampicillin sodium 
salt, tetracycline, and human serum were purchased from Sigma (St. Louis, MO).  
Urea, 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES), and 
glycerol were purchased from BDH/VWR (Bridgeport, NJ).  Dimethylsulfoxide 
(DMSO) was purchased from J.T. Baker (Phillipsburg, NJ).  Isopropyl β-D-1-
thiogalactopyranoside (IPTG) was purchased from Gold Biotechnology (St. 
Louis, MO).  Maltose was purchased from Acros (Pittsburg, PA).  QIAquick gel 
purification kit and QIAprep DNA isolation kit were purchased from Qiagen 
(Valencia, CA).  5-((((2-iodoacetyl)amino)ethyl)amino)naphthalene-1-sulfonic 
acid (IAEDANS), TOP10F’ cells, and the vector pRSETA were obtained from 
Invitrogen (Carlsbad, CA).  Ten thousand molecular weight cut-off dialysis 
cassettes were purchased from Pierce (Rockford, IL).  Amylose resin and the 
vector pMal-p4E were purchased from New England Biolabs (Ipswich, MA). 
Apparatus.  PCR reactions were carried out using an Eppendorf Mastercycler 
personal thermocycler (Hamburg, Germany).  Optical density (OD) 
measurements were performed using a Milton Roy Spectronic 21D 
spectrophotometer (Ivyland, PA).  Cell lysis was performed using a Fisher Sonic  
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Table 3.1.  Assay response of selected OH-PCBs 
Compound 
Detection 
Limit (M) 
Apparent 
KD (M) Dynamic Range (M) 
2,3-Dihydroxy-3',4'-dichlorobiphenyl N/A N/A N/A 
2-Hydroxy-2',3',4',5,5'-pentachlorobiphenyl 1.0 x 10-6 2.5 x 10-6 1.0 x 10-6 – 1.0 x 10-4 
2-Hydroxy-2',3,4',5',6-pentachlorobiphenyl 1.0 x 10-6 2.4 x 10-6 1.0 x 10-6 – 1.0 x 10-5 
2-Hydroxy-2',3',4',5-tetrachlorobiphenyl 1.0 x 10-7 2.1 x 10-6 1.0 x 10-6 – 1.0 x 10-5 
2-Hydroxy-2',3',5',6'-tetrachlorobiphenyl 1.0 x10-8 2.4 x 10-7 1.0 x 10-8 – 1.0 x 10-6 
2-Hydroxy-2',4',5,6'-tetrachlorobiphenyl 1.0 x 10-7 1.3 x 10-7 1.0 x 10-7 – 1.0 x 10-6 
2-Hydroxy-2',4',6-trichlorobiphenyl 3.2 x 10-7 1.0 x 10-6 3.2 x 10-7 – 1.0 x 10-5 
2-Hydroxy-3',4'-dichlorobiphenyl 1.0 x 10-7 2.3 x 10-7 1.0 x 10-7 – 1.0 x 10-5 
2-Hydroxy-3',5,5'-trichlorobiphenyl N/A N/A N/A 
4-Hydroxy-2',3,4',5-tetrachlorobiphenyl 1.0 x 10-6 2.5 x 10-6 1.0 x 10-6 – 1.0 x 10-4 
4-Hydroxy-2',3',5-trichlorobiphenyl 1.0 x 10-7 1.0 x 10-6 1.0 x 10-7 - 1.0 x 10-5 
4-Hydroxy-2',4',6'-trichlorobiphenyl 1.0 x 10-7 9.6 x 10-7 1.0 x 10-7 - 1.0 x 10-5 
4-Hydroxy-3,3',4',5-tetrachlorobiphenyl 1.0 x 10-7 1.0 x 10-6 1.0 x 10-7 - 1.0 x 10-5 
4-Hydroxy-3,3',5'-trichlorobiphenyl 1.0 x 10-8 6.1 x 10-7 1.0 x 10-8 - 1.0 x 10-5 
4-Hydroxy-3,5-dichlorobiphenyl 1.0 x 10-8 5.6 x 10-8 1.0 x 10-8 - 1.0 x 10-6 
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Dismembrator 500 from Fisher (Fair Lawn, NJ).  Centrifugation steps were 
carried out using a Beckman Coulter Avanti J-E centrifuge from Beckman Coulter 
(Palo Alto, CA).  Fluorescence measurements were performed using a BMG 
Labtech POLARstar Optima microtiter plate fluorimeter from BMG (Offenburg, 
Germany). 
Construction of pHbpR-A-MBP plasmid.  For all cloning and culturing steps, 
cells were grown in LB supplemented for selection as described below.  Cell 
cultures were grown at 37 °C, with shaking at 250 rpm.  Initially, the gene for the 
A-domain of HbpR (hbpR-A) was amplified by PCR using the procedure provided 
by the supplier of the Pfu polymerase.  The primers used were HbpR-A-BamHI 
(5’-GGTGGTGGATCCATGAAATCAAATAAAAATAATAGC-3’) and HbpR-A-
EcoRI (5’-GGTGGTGGATTCCGCCCACATTTCGGCGGGCTTCGC-3’).  The 
template DNA used was pHYBP109 and was obtained from our previous work.[4]  
PCR reaction conditions were carried out as described by the supplier’s protocol.  
Briefly, the reaction mixture contained final concentrations of 2.5 µM for each 
primer and 25 ng/µL of template DNA.  The temperature program used for 
amplification consisted of an initial denaturation step of 95 °C for 2 min, followed 
by 30 cycles of 95 °C for 1 min, 65 °C for 2 min, and 72 °C for 2 min and a final 
elongation step of 72 °C for 5 min. 
The resulting PCR product was purified by agarose gel electrophoresis, 
and the corresponding DNA band (617 bp) was excised from the gel and purified 
using the QIAquick Gel Extraction Kit.  The purified PCR product, in tandem with 
the vector pRSETA, was then digested with the restriction enzymes BamHI and 
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EcoRI following the supplier’s protocol.  The digested fragments were purified by 
agarose gel electrophoresis, co-purified using the QIAquick Gel Extraction Kit, 
and ligated using T4 ligase following the supplier’s protocol.  The resulting 
ligation product was transformed into TOP10F’ cells, which were grown on LB 
agar with ampicillin (100 µg/mL) and tetracycline (15 µg/mL) for selection. 
Transformation colonies were grown overnight in LB media with ampicillin 
and tetracycline.  Plasmid from these cultures was isolated using the QIAprep kit, 
digested with BamHI and EcoRI, and analyzed by agarose gel electrophoresis for 
the correct plasmid, pRSETA-hbpR-A.  The purified plasmid possessing bands of 
the correct size was sequenced for confirmation.  For transformants containing 
plasmids with the correct sequence, glycerol stocks were prepared and stored at 
-80 °C. 
To prepare a plasmid for expression of the A-domain of HbpR (HbpR-A) 
as a fusion to maltose binding protein (MBP), the plasmids pRSETA-hbpR-A and 
pMal-p4E were digested with BamHI and HindIII.  The resulting products were 
purified by agarose gel electrophoresis, co-isolated from the gel using the 
QIAquick Gel Extraction Kit and ligated using T4 ligase as above.  The resulting 
product was transformed into TOP10F’ cells and grown on LB agar with 
ampicillin and tetracycline for selection.  As above, the transformants were 
analyzed for the correct plasmid, pMal-p4E-hbpR-A, and candidates were sent 
for confirmation by DNA sequencing.  Transformants containing the correct 
plasmid were preserved as glycerol stocks at -80 °C. 
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Expression and Purification of HbpR-A-MBP.  For expression of HbpR-A-
MBP, a 2.0 mL culture of TOP10F’ cells containing pMal-p4E-hbpR-A was grown 
overnight in LB media supplemented with ampicillin (100 µg/mL) and tetracycline 
(15 µg/mL).  Two 500 mL expression cultures in LB media were inoculated the 
following day using the overnight cultures and grown to an OD600 of 0.4-0.5, and 
protein expression was induced by the addition of 1 mM IPTG.  Expression was 
carried out overnight at 37 °C.  Following expression, the cultures were 
centrifuged to a pellet (10,000 x g, 20 min, 4 °C), and the supernatant was 
discarded.  The isolated cell pellet was used to prepare purified HbpR-A-MBP 
fusion protein. 
The cell pellet was resuspended in lysis buffer (20 mM Tris-HCl, 200 mM 
NaCl, 1 mM EDTA, pH 7.4) and placed on ice.  Cells were lysed on ice by pulsed 
sonication (10 s on, 10 s off, 10 min total), and the resulting suspension was 
immediately centrifuged (10,000 x g, 20 min, 4 °C) to separate the protein-
containing supernatant from the cellular debris.  The supernatant was added to a 
gravity-flow column containing 2 mL of amylose resin equilibrated according to 
the supplier’s instructions, and the flow-through fraction was collected.  The 
column was washed with 16 mL of lysis buffer, and the fraction was collected.  
Finally, the fusion protein was eluted from the column in 9 aliquots of 0.5 mL of 
lysis buffer containing an increasing concentration of maltose (1 mM for fraction 
1, 2 mM for fraction 2, 5 mM for fraction 3, and 10 mM for fractions 4-9).  All 
purification fractions were analyzed by SDS-PAGE electrophoresis to determine 
the purity of the expressed protein.  Fractions containing significant impurities 
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were discarded, and purified protein was combined and dialyzed in 1 L of 
labeling buffer (20 mM HEPES, pH 7.2) overnight at 4 °C. 
Labeling HbpR-A-MBP with IAEDANS.  The thiol-reactive, environmentally-
sensitive fluorophore IAEDANS was used for protein labeling.  Protein 
modification was carried out according to the Invitrogen Molecular Probes 
handbook for thiol-reactive probes.  Briefly, the protein was denatured and 
possible disulfide bonds were reduced by reacting 3.0 mL of the protein in 
labeling buffer containing 1 mM TCEP and 6 M urea for 2 h at 4 °C with stirring.  
Following this reaction, 10 µL of a 2.3 x 10-2 M stock of IAEDANS in DMSO was 
added to the same vial, resulting in a 10-fold molar excess of IAEDANS with 
respect to the number of cysteines present.  This mixture was allowed to react in 
an amber glass vial in the dark overnight at 4 °C with stirring.  Following the 
labeling reaction, the solution was dialyzed extensively at 4 °C to remove any 
free IAEDANS from solution and to gradually remove urea and allow protein 
refolding.  The reaction solution was placed inside of a 10,000 molecular weight 
cut-off, 10 mL dialysis cassette and dialyzed in an initial dialysis buffer (20 mM 
HEPES, 2 M urea, 0.2 mM EDTA, pH 7.4) for 7 h at 4 °C with mixing in the dark.  
Following this, consecutive buffer changes were performed by removing half of 
the dialysis buffer and replacing with dialysis buffer with no urea, halving the 
previous urea concentration.  Each dialysis step was carried out for at least 4 h.  
This was repeated 5 times, and then a final dialysis was carried out replacing the 
entire volume of dialysis buffer.  The thoroughly dialyzed protein solution was 
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then removed from the dialysis cassette, placed in an amber glass vial, and 
stored at 4 °C. 
Fluorescence Assays of OH-PCBs in Buffer.  For fluorescence assays in 
buffer, stock solutions of selected OH-PCBs were prepared at a concentration of 
1 x 10-2 M in DMSO.  From these stock solutions, standards were prepared by 
serial dilution in DMSO resulting in a range of concentrations from 1 x 10-2 M to 1 
x 10-8 M.  Using these DMSO standards, assay standards were prepared by 
diluting each DMSO standard 1:10 into assay buffer (10 mM HEPES, pH 7.5), 
resulting in assay standards with a range of concentrations from 1 x 10-3 M to 1 x 
10-9 M.  An assay blank was also prepared by preparing a 10% (v/v) solution of 
DMSO in assay buffer.  To perform assays of the compounds, 180 µL of the 
HbpR-A-MBP-IAEDANS solution at a concentration of 1 x 10-7 M was mixed with 
20 µL of assay standards, as well as a blank sample, in triplicate.  The 
fluorescence was measured using a BMG Labtech Polarstar Optima microtiter 
plate fluorimeter.  Data were plotted using GraphPad Prism 5.0 (GraphPad 
Software, San Diego, CA) with a three-parameter sigmoidal curve fitting 
equation, and apparent binding constants were derived from this equation.  
Detection limits were determined as the concentration tested that produced a 
signal intensity that is at least 3 standard deviations above the blank signal. 
Fluorescence Assay of 2-Hydroxy-3’,4’-dichlorobiphenyl in Human Serum.   
The assay of 2-hydroxy-3’,4’-dichlorobiphenyl was carried out in human serum.  
The procedure was carried out as above for the preparation of standards, except 
that in the preparation of assay standards, purchased human serum was used 
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instead of buffer.  The resulting serum samples contained the OH-PCB in a 
concentration range of 1 x 10-3 M – 1 x 10-9 M.  Using these standards, the assay 
procedure above was followed precisely. 
 
RESULTS AND DISCUSSION 
 HbpR is a member of the XylR/DmpR subclass of the NtrC family of 
regulatory proteins from bacteria.[146]  This family of proteins typically contains 
four distinct domains (figure 3.1).  The effector binding domain, or A-domain, 
interacts directly with an effector molecule and begins a drastic conformational 
change, which is relayed to the rest of the protein through a helix linker region in 
the B-domain.  The conformational change is then translated to the C-domain, 
whose ATP-ase activity is triggered, which then recruits the σ54 RNA polymerase.  
Simultaneously, the DNA-binding D-domain undergoes a conformational change, 
which triggers its release from the operator region of the DNA resulting in 
expression of genes under the control of the associated promoter.[146]  In the 
subclass of proteins encompassing XylR, DmpR, and HbpR, the effector 
molecule is aromatic, and it has been demonstrated that the isolated A-domain 
binds to its aromatic effector molecule in vitro.[147]       
 Members of this class of proteins are particularly difficult to express, 
purify, and stabilize in solution, and as a result structural information for members 
of this class of proteins has been difficult to acquire.[145, 148]  Any structural 
information that has been obtained thus far is the result of modeling the structure 
of these proteins using as a template other proteins, which are very distantly 
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related and lack a high degree of homology.[145, 148]  This lack of specific 
information on the overall protein structure, coupled with the lack of detailed 
information on the conformational change that occurs upon effector molecule 
binding makes it nearly impossible to rationally-design a protein that will generate 
a measurable change in signal upon analyte binding.   
 As an alternative, we have taken a shot-gun approach by attaching a 
fluorophore simultaneously to cysteines present in HbpR.  Several strategies for 
expressing and purifying in significant quantities either the entire HbpR protein, 
or the isolated A-domain, HbpR-A were attempted.  Initially, the genes for the 
expression of HbpR and HbpR-A were cloned into the expression vector 
pRSETA.  This expression system is designed to express the protein with an N-
terminal histidine tag.  This system yielded small amounts of insoluble protein for 
both HbpR and HbpR-A; subsequent attempts to denature and refold the protein 
were unsuccessful (data not shown).  In order to improve protein solubility, we 
cloned the genes for both the full-length and truncated protein into the expression 
vector pMAL-p4E, which expresses the protein as a C-terminal fusion to MBP.  
Maltose binding protein possesses exceptional solubility and often confers this 
property upon its protein fusion partner.  Indeed, when expressed as a fusion we 
were able to obtain soluble, purified HbpR-A-MBP.  The HbpR-MBP fusion 
protein was insoluble upon expression.  Attempts to cleave HbpR-A from MBP 
and purify isolated HbpR-A were also unsuccessful, as the protein immediately 
precipitated.  For these reasons, this work focuses on the use of the HbpR-A-
MBP fusion protein. 
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 Extensive characterization of HbpR has been carried out previously.  The 
selectivity of HbpR has been well-defined by initial work carried out by Jaspers et 
al. and expanded by our previous work.[4, 146]  HbpR shows the greatest 
response to its native effector, 2-hydroxybiphenyl, but also has been shown to 
respond to some structurally related compounds such as 2,2’-dihydroxybiphenyl, 
2-aminobiphenyl, 2-hydroxydiphenylmethane and many OH-PCBs.  However, all 
previous work with this protein was accomplished in a cell-based sensing 
approach.  The isolated protein has never been directly used in vitro to 
investigate the binding of any of these molecules. 
 The purified fusion protein was labeled with an environmentally-sensitive 
fluorophore, IAEDANS.  An initial assay using this protein, HbpR-A-MBP-
IAEDANS, with standards of the compound 2-hydroxy-3’,4’-dichlorobiphenyl in 
buffer demonstrated that the protein did indeed respond in a dose-dependent 
manner (figure 3.2), with a limit of detection of 1.0 x 10-7 M.  The assay for 2-
hydroxy-3’,4’-dichlorobiphenyl was also carried out in spiked human serum.  A 
concentration-dependent response was observed in both sample matrices, 
although the blank-subtracted fluorescence intensity was slightly lower in serum 
samples, and the detection limit was an order of magnitude higher.  This could be 
because the analyte may associate with proteins in serum making it less 
available to the protein-based sensor.  However, the ability to detect OH-PCBs 
directly in serum with no sample pretreatment is a significant improvement over 
current detection methods.   
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Figure 3.2.  Dose-response curves for 2-Hydroxy-3’,4’-dichlorobiphenyl in 
buffer and spiked human serum.  The assay was carried out by mixing 20 µL 
of each standard in either buffer (■) or serum (●) with 180 µL of 1 x 10-7 M HbpR-
A-MBP-IAEDANS and measuring immediately after mixing.  The samples were 
prepared in triplicate, the results were averaged, and the signal of the blank was 
subtracted.  The results were fitted with a sigmoidal response curve.  Error bars 
denote +/- one standard deviation. 
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 To investigate the effect of incubation time on assay performance, the 
signal from a single microtiter plate assay was measured immediately after 
addition of the analyte.  Additional fluorescence measurements of the same 
microtiter plate were performed at 15 min, 45 min, and 105 min.  While there was 
a gradual decrease in the total fluorescence intensity of the measurements with 
time, the detection limit and dynamic range were not improved at longer 
incubation times (Figure 3.3).  For this reason, all measurements were performed 
with no additional incubation time. 
 In order to investigate the response characteristics of the biosensing 
system, additional assays were carried out for the detection of other OH-PCBs as 
listed in table 3.1.  The biosensing system responded to most of the OH-PCBs 
tested, with the exception of 2-hydroxy-3',5,5'-trichlorobiphenyl and 2,3-
dihydroxy-3',4'-dichlorobiphenyl.  In previous work in our laboratory, our whole-
cell sensing system seemed to respond to the former.  It is unclear why the 
isolated protein would fail to respond to this compound.  However, our whole-cell 
sensing system failed to respond to any dihydroxy compounds, so it is 
unsurprising that the isolated protein shows no response to the latter.  Since in 
our protein biosensing system, HbpR-A is expressed as a fusion to MBP, which 
contains one cysteine that could be modified with IAEDANS, we conducted the 
assay using MBP-IAEDANS with 2-hydroxybiphenyl to confirm that no response 
was observed from MBP alone (data not shown).  This was done to ensure that 
the response we were observing was due to HbpR-A and not to MBP.   
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Figure 3.3.  Time study of 2-Hydroxy-2’,3’,5’,6’-tetrachlorobiphenyl in buffer.  
The assay was carried out by mixing 20 µL of each standard in buffer with 180 
µL of 1 x 10-7 M HbpR-A-MBP-IAEDANS and measuring immediately (●), after 
45 min (■), and after 105 min (▲).  The samples were prepared in triplicate, the 
results were averaged, and the signal of the blank was subtracted.  Error bars 
denote +/- one standard deviation. 
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Detection limits for the compounds assayed ranged from 1 x 10-8 M to 1 x 10-6 M, 
and the dynamic range varied from one to three orders of magnitude (Table 3.1).  
The percent relative standard deviation (%RSD) was calculated for each of the 
data points for all of the compounds as an evaluation of intra-assay 
reproducibility.  The %RSD ranged from 0.01 to 10.8.  Additionally, the %RSD 
was calculated using data from repeated assays of the same compound, 2-
hydroxy-3’,4’-dichlorobiphenyl in order to evaluate inter-assay variability and 
found to range from 1.1 to 2.3.  These data suggest that the assay is 
reproducible.   
 It is hypothesized that the differing response to various OH-PCBs is due to 
structural differences between the molecules, which would affect their interaction 
with the binding pocket of HbpR-A.  Without the availability of detailed structural 
information of the protein only inferences can be made to explain the variations in 
response.  To gain some insight into the observed variation in the response to 
different compounds, correlation analysis was performed on the data.  Spearman 
correlation analyses were performed on the basis of a number of characteristics 
that differentiate OH-PCB congeners (Table 3.2).  First, the dihedral angle 
between the two aromatic rings of each molecule was calculated.  This was 
accomplished by modeling the energy-minimized 3D structure of the compounds 
using Chem3D Pro 12.0 (CambridgeSoft, Cambridge, MA)  The dihedral angle 
reflects the planarity of each molecule.  In general, substitutions in the ortho- 
positions on each ring contribute to a less planar conformation for the OH-PCBs.   
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Table 3.2.  Molecular characteristics of selected OH-PCBs 
Compound Volume (Å3) logP Dihedral Angle (°) 
2,3-Dihydroxy-3',4'-dichlorobiphenyl 171.3 4.25 22 
2-Hydroxy-2',3',4',5,5'-pentachlorobiphenyl 209.3 6.62 42 
2-Hydroxy-2',3,4',5',6-pentachlorobiphenyl 210.6 6.62 56 
2-Hydroxy-2',3',4',5-tetrachlorobiphenyl 195.0 6.01 41 
2-Hydroxy-2',3',5',6'-tetrachlorobiphenyl 197.7 5.59 60 
2-Hydroxy-2',4',5,6'-tetrachlorobiphenyl 197.6 5.64 57 
2-Hydroxy-2',4',6-trichlorobiphenyl 182.5 5.38 54 
2-Hydroxy-3',4'-dichlorobiphenyl 164.9 4.75 21 
2-Hydroxy-3',5,5'-trichlorobiphenyl 179.1 5.40 22 
4-Hydroxy-2',3,4',5-tetrachlorobiphenyl 193.4 6.01 29 
4-Hydroxy-2',3',5-trichlorobiphenyl 179.2 5.38 31 
4-Hydroxy-2',4',6'-trichlorobiphenyl 180.6 4.78 44 
4-Hydroxy-3,3',4',5-tetrachlorobiphenyl 192.2 6.01 1 
4-Hydroxy-3,3',5'-trichlorobiphenyl 178.6 5.40 0 
4-Hydroxy-3,5-dichlorobiphenyl 163.6 4.73 0 
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The solvent exclusion volume that each molecule would be expected to occupy 
was also calculated using Chem3D Pro 12.0.  This value may influence the 
affinity to the binding pocket, as molecules that are either too large or too small 
would not be expected to bind well.  Lastly, the partition coefficient, logP, which is 
a reflection of the hydrophobicity of each molecule, was calculated using 
ChemDraw Ultra 12.0 (CambridgeSoft, Cambridge, MA).  These values are 
predicted using a fragmentation method based on atomic contributions from a 
large reference set of molecules by least squares analysis.  Since the effector 
molecules that bind to HbpR are hydrophobic, it is expected that the binding 
pocket of HbpR is a hydrophobic binding pocket located on the interior of the A-
domain.  Additionally, binding pockets located in the interior of proteins are 
typically a hydrophobic environment.  For this reason, the hydrophobicity of 
different congeners may affect the binding interaction.   
 Correlation analyses for each of these parameters were carried out with 
respect to the detection limits and apparent KD values observed in the assay 
data.  There was no significant correlation calculated between either the 
detection limits or apparent KD values and the dihedral angles or the molecular 
volumes.  However there was a slight correlation (r = 0.5885, p = 0.0344) 
between the detection limits and the partition coefficients and an even stronger 
correlation (r = 0.7406, p = 0.0038) between the apparent KD values and the 
partition coefficients (figure 3.4).  This would suggest that as the hydrophobicity 
of the molecules increases so do both the detection limit and the apparent KD 
value.  A possible explanation of this behavior is that the position of the hydroxy  
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Figure 3.4.  Correlation analysis of logP values and apparent binding 
affinities.  Apparent binding affinities, KD, were calculated by GraphPad Prism 
5.0 software from sigmoidal response curves obtained from the assay of each 
compound.  Values of logP were obtained using ChemDraw Ultra 12.0.  A 
Spearman correlation analysis was performed between the two parameters using 
GraphPad Prism 5.0 software.  The calculated correlation value was 0.7406 (p = 
0.0038).  
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functionality is important and determines to some extent how HbpR interacts with 
the effector molecules.  There may be one or more hydrophilic amino acids 
present within the binding pocket of HbpR that participate in hydrogen-bonding 
interactions with the hydroxy-group.  Interestingly it appears that it is not the 
position of the chlorine substituents from various OH-PCBs that determines 
strength of interaction through steric hindrance, but rather the relative 
hydrophobicity of the OH-PCBs.  This suggests that the binding pocket may be 
large and hydrophobic and as such be able to accommodate a wide range of 
structurally related compounds.  To be able to ascertain this with a high degree 
of confidence would require the availability of the three-dimensional structure of 
HbpR.   
 
CONCLUSION 
 We have developed a protein-based sensing system for the detection of 
OH-PCBs by the covalent attachment of the fluorophore IAEDANS to cysteines 
present in the effector binding domain of the transcriptional regulatory protein 
HbpR.  We have demonstrated the dose-dependent response in buffer as well as 
in a sample matrix of human serum.  This biosensing system responds broadly to 
most OH-PCBs tested resulting in detection limits as low as 1 x 10-8 M, which 
should enable its application as a rapid, cost-effective, high-throughput screening 
method for large numbers of samples suspected of containing OH-PCBs.  This 
should lead to the identification of positive samples to be subjected to a more in-
depth analysis by other analytical methods such as GC-MS.  Ongoing structural 
90 
 
studies of HbpR should eventually provide more detailed structural information, 
which will provide for the rational design of the protein to improve its response 
characteristics and allow for the development of a biosensing system with more 
desirable properties, such as, improved detection limits, selectivity, and response 
to more highly chlorinated OH-PCBs. 
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CHAPTER FOUR 
ENGINEERING GLUCOSE RECOGNITION PEPTIDES FROM NATURE: 
SELECTIVE AND SENSITIVE BIOSENSORS FOR GLUCOSE 
 
INTRODUCTION 
The development of reliable, low cost technologies for glucose sensing 
has been an active field of research since the first glucose biosensing device was 
proposed in 1962.[96, 149]  While recent generations of these devices have seen 
improvements in performance, the basic principles of the technology have 
remained almost identical.  Current-generation commercially available glucose 
meters measure glucose by electrochemical methods based on the enzymes 
glucose oxidase (GOx) or glucose-1-dehydrogenase (GDH).[149]  These 
electrochemical methods suffer from some significant drawbacks including 
hematocrit dependence, interference from other electrochemically active 
molecules, hypoxemia, or hypotension.[149]  Lack of electrochemical selectivity 
is especially troublesome, as the list of potentially interfering compounds includes 
molecules commonly found in blood such as acetaminophen, salicylic acid, 
ibuprofen, ascorbic acid, etc.[96, 150] 
To overcome the disadvantages of electrochemical methods for glucose 
sensing, methods based on alternative technologies have been proposed and 
are currently being evaluated.  To that end, the design and development of 
reagentless optical sensing strategies that are sensitive, selective, reproducible, 
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accurate, rugged, and capable of glucose detection in the physiological 
concentrations and conditions is an active field of research.  Among these 
methods are fluorescence-based,[89, 151, 152] fluorescence resonance energy 
transfer (FRET)-based,[151, 152]  and bioluminescence-based[72] methods.  In 
each of these cases, the glucose/galactose binding protein (GBP) (Figure 4.1) 
from Escherichia coli is employed as the biological recognition element.  GBP is 
a well-studied periplasmic binding protein consisting of 309 amino acids, which 
undergoes a hinge-motion conformational change upon binding glucose or 
galactose.  As outlined in the examples mentioned above, this conformational 
change has been exploited in a variety of ways to produce a measurable optical 
signal in response to glucose.  As a result of these methods relying on an optical 
response, many of the drawbacks of electrochemically-based detection of 
glucose, such as interference from other molecules are circumvented.  
While biosensing systems based upon GBP address some of the shortcomings 
of electrochemical-based systems, the relatively low dissociation constant (KD) of 
GBP (in the micromolar range) compared to the physiological concentration of 
glucose (in the millimolar range) constrains GBP’s widespread implementation 
into commercial devices.  Efforts to alter the binding affinity of proteins by 
affecting changes in the amino acid sequence have included site-directed 
mutagenesis,[151, 153] random mutagenesis,[154] and DNA shuffling.[155]  
These efforts have resulted in proteins with affinities shifted to the millimolar 
range, however the selectivity toward glucose against other sugars and 
glycosylated moeities has not been fully determined.  These approaches may  
93 
 
 
 
Figure 4.1.  Protein structures for native GBP and tGRPs.  Native GBP (a.) is 
shown with galactose in the ligand-binding pocket and calcium (shown in green) 
present in the calcium-binding pocket (PDB ID: 1GLG).  In (b.), the binding 
pocket is magnified showing the amino acids involved in hydrogen bonding with 
glucose as well as Cys152.  tGRP1 (b.), tGRP2 (c.), and tGRP3 (d.) are shown 
with truncated areas of the protein in red. 
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significantly alter the inherent selectivity of the protein, as they involve 
introducing significant changes into the binding pocket; thus the applicability of 
these systems for glucose sensing may be somewhat compromised.   
 In this work, we hypothesize that by rationally engineering the protein to 
truncate portions of GBP, we can construct truncated glucose recognition 
peptides (tGRPs), which maintain the wild-type GBP’s response to glucose while 
altering the dissociation constant of the protein by affecting the overall folding 
and structure of the protein.  In the design of these proteins, it is important to 
maintain much of the hydrogen-bonding network that is responsible for the direct 
interaction with glucose, as well as the hinge region connecting the two lobes, so 
that the integrity of the binding is preserved.  Herein, we present a series of 
newly designed tGRPs, their characterization, and their use in glucose sensing.  
EXPERIMENTAL PROCEDURES 
Reagents.  All oligonucleotide primers were purchased from Operon 
Biotechnologies (Huntsville, AL).  Phusion DNA polymerase was purchased from 
New England Biolabs (Ipswich, MA).  2-Amino-2-hydroxymethyl-propane-1,3-diol 
(Tris-base), β-mercaptoethanol, bovine serum albumin (BSA), dimethyl sulfoxide 
(DMSO), calcium chloride (CaCl2), ampicillin sodium salt, tetracycline, ethidium 
bromide, agarose, 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid 
(HEPES), and D-glucose, sucrose, and lactose, and D-galactose were obtained 
from Sigma-Aldrich (St. Louis, MO).  Glycine, sodium chloride, 
ethylenediaminetetraacetic acid (EDTA), and Luria-Bertani (LB) broth and agar, 
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were purchased from Fisher Scientific (Fair Lawn, NJ).  Methanol, acetic acid, 
sodium phosphate dibasic, sodium phosphate monobasic, glycerol, and 
bromophenol blue were purchased from VWR (Bridgeport, NJ).  Imidazole and 
maltose were purchased from J.T. Baker (Phillipsburg, NJ).  Isopropyl β-D-1-
thiogalactopyranoside (IPTG) and dithiothreitol (DTT) were purchased from Gold 
Biotechnology (St. Louis, MO).  Sodium dodecyl sulfate was ordered from Curtin 
Matheson (Houston, TX).  The Bradford protein assay kit was purchased from 
Biorad (Hercules, CA).  Ni-NTA agarose resin, QIAquick gel purification kit, 
QIAprep DNA isolation kit, and the pQE70 vector were purchased from Qiagen 
(Valencia, CA).  TOP10F’ cells, Tris-Glycine SDS PAGE gels, 7-diethylamino-3-
((((2-maleimidyl)ethyl)amino)carbonyl)coumarin (MDCC), Mark12 protein 
standard, and 1 kb DNA standard were purchased from Invitrogen (Carlsbad, 
CA).  Three thousand five hundred MWCO Slide-A-Lyzer 3-12 mL dialysis 
cassettes were purchased from Pierce (Rockford, IL).  T4 DNA ligase, SphI 
restriction enzyme and BglII restriction enzyme were purchased from Promega 
(Madison, WI). 
Apparatus.  Polymerase chain reactions (PCR) were performed using an 
Eppendorf Mastercycler Personal Thermocycler (Hauppauge, NY). 
Electrophoresis of DNA was carried out using an FB105 Fischer Biotech 
Electrophoresis Power Supply (Pittsburg, PA).  DNA gels were visualized using a 
UV Transilluminator platform from UVP (Upland, CA).  Optical density 
measurements were obtained using a Spectronic 21D from Milton Roy (Ivy Land, 
PA).  Cells were lysed using a 550 Sonic Dismembrator from Fisher Scientific 
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(Pittsburg, PA). Proteins were expressed by incubating bacteria at 37 oC on a 
Forma Scientific Orbital Shaker (Fairlawn, NJ).  All centrifugations were carried 
out using a Beckman J2MI centrifuge (Palo Alto, CA).  Proteins were visualized 
by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) using 
Invitrogen 10-20% Tris-glycine gels in an Invitrogen X Cell Sure Lock Mini Cell 
(Carlsbad, CA).  Fluorescence measurements were obtained using a 
QuantaMaster 40 Spectrofluorometer from PTI (Birmingham, NJ).  Circular 
dichroism measurements were taken using a Jasco J-810 Spectropolarimeter 
(Easton, MD).  DNA sequencing was performed by the Advanced Genetic 
Testing Center at the University of Kentucky. 
Cloning of Truncated Glucose Recognition Peptides (tGRPs).  To prepare 
tGRPs, various segments of the full-length glucose binding protein (GBP) 
containing a mutation introducing a unique cysteine in place of histidine at 
position 152 from Escherichia coli (E. coli) were amplified by PCR and ligated 
into the expression vector pQE70.  Specifically, gene fragments were amplified 
corresponding to amino acids 14-296 (tGRP1), 14-256 (tGRP2), and 87-271 
(tGRP3) of the native sequence.   For the amplification of tGRP1, primers 
tGBP(14-)fwd [5’-GGTGGTGCATGCGCGATAACTTTATGTCTGTAGTGCGG-3’] 
and tGBP(-296)rev [5’-GGTGGTAGATCTAACATAAGGTACGCGGACCAC-3’] 
were used.  For the amplification of tGRP2, primers tGBP(14-)fwd and tGBP(-
256)rev [5’-GGTGGTAGATCTGTTCAGTACGGTGCCCGCCAG-3’] were used.  
For the amplification of tGRP3, primers tGBP(87-)fwd [5’- 
GGTGGTGCATGCGCGTGGTTTTCTTCAACAAAGAACCG-3’] and tGBP(-
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271)rev [5’-GGTGGTAGATCTGTTTTTCGCCAGATCAAAGGTCGC-3’] were 
used.  PCR was carried out using Phusion High-Fidelity DNA Polymerase.  PCR 
conditions consisted of an initial denaturation period of 30 s at 98 °C.  Next, 30 
cycles of 98 °C for 30 s, 70 °C for 30 s, and 72 °C for 60 s followed by a final 
elongation period of 72 °C for 5 min were carried out.  The resulting reaction 
products were analyzed by tris-acetate-EDTA (TAE) 1% agarose gel 
electrophoresis, and the appropriate DNA fragments (861 bp for tGRP1, 741 bp 
for tGRP2, and 567 bp for tGRP3) were excised from the gel and purified using 
the QIAquick gel extraction kit.   
The DNA fragments tGRP1, tGRP2, and tGRP3 along with expression 
vector pQE70 were digested with restriction enzymes BglII and SphI.  The 
resulting products were analyzed by TAE 1% agarose gel electrophoresis, 
excised from the gel, and purified using the QIAquick gel extraction kit.  A gel 
slice of digested pQE70 was co-purified in each separate tube containing tGRP1, 
tGRP2, and tGRP3 allowing the vector and insert to be eluted from the 
purification column simultaneously.  To the eluted DNA, T4 DNA ligase and T4 
DNA ligase buffer (10x) were added, and the ligation reaction was allowed to 
proceed overnight at room temperature.  The ligated DNA was transformed into 
TOP10F’ cells.  Plasmid DNA was isolated from overnight cultures of selected 
transformants and analyzed for the presence of the desired DNA fragments by 
digestion with BglII and SphI.  DNA sequencing was also performed to confirm 
the correct DNA sequence. 
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tGRPs Expression and Purification.  Plasmids tGRP1 and tGRP2 were 
transformed into TOP10F’ chemically-competent cells.  For protein expression, 
cells were grown overnight at 37 °C with shaking in 3 mL of LB broth containing 
ampicillin (100 µg/mL) and tetracycline (12.5 µg/mL) for selection.  The following 
day in a 1 L flask, 500 mL of LB broth containing ampicillin (100 µg/mL)  and 
tetracycline (12.5 µg/mL) was inoculated with the overnight culture and grown at 
37 °C with shaking at 250 rpm to an OD600 of 0.4-0.5.  Protein expression was 
then induced with IPTG at a final concentration of 1.0 mM.  The expression 
culture was grown overnight at room temperature with shaking. 
For protein purification, the culture expressing the desired proteins was 
centrifuged to a pellet at 12000 x g for 20 min at 4 °C, and the supernatant was 
removed and discarded.  The bacterial cell pellet was resuspended in 15 mL lysis 
buffer (50 mM NaH2PO4, 30 mM NaCl, 10 mM imidazole, pH 8.0) and lysed by 
sonication on ice using a programmed cycle of 10 s on, 10 s of, for 10 min total.  
The cell debris was pelleted by centrifugation 12000 x g for 20 min at 4 °C, and 
the resulting crude protein-containing cell-extract was removed to a separate 
culture tube.  To the crude extract, 1.0 mL of Ni-NTA resin was added and mixed 
at 4 °C for 1 h.  The solution was then added to a gravity-flow column, and the 
flow through was collected.  The resin was washed with 20 mL of wash buffer (50 
mM NaH2PO4, 30 mM NaCl, 20 mM imidazole, pH 8.0), and the wash fraction 
was collected.   Purified protein was eluted from the column in 1.0 mL aliquots of 
elution buffer (50 mM NaH2PO4, 30 mM NaCl, 250 mM imidazole, pH 8.0).  All 
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collected fractions were analyzed by SDS-PAGE electrophoresis, and fractions 
containing purified protein were combined and stored at 4°C. 
tGRPs Modification with Fluorophore.  Purified proteins were reacted with an 
excess of DTT to reduce possible disulfide bonds between two molecules of 
tGRP.  Excess DTT was removed by dialysis in 3500 MWCO dialysis cassettes 
in dialysis buffer (10 mM HEPES, 0.2 mM CaCl2, pH 8.0).  The dialyzed protein 
was reacted with a 10-fold molar excess of MDCC dissolved in DMSO, using 
manufacturer’s instructions.  The labeling reaction was carried out overnight at 4 
°C in an amber glass vial, protected from light.  Following the labeling reaction, 
the protein was extensively dialyzed against dialysis buffer (as above) to remove 
any excess MDCC.  Labeled proteins were stored at 4 °C, protected from light. 
Assay of Glucose with MDCC-labeled tGRPs.  For the glucose assay, MDCC-
labeled protein was used at a final concentration of 1 x 10-7 M in assay buffer (10 
mM HEPES, 0.2 mM CaCl2, pH 8.0).  Glucose standards were freshly prepared 
in assay buffer by serial dilution using a freshly prepared 0.1 M glucose solution.  
For the assay, 180 µL of the labeled protein solution was added to 20 µL of each 
standard, as well as a blank, in triplicate and mixed gently and thoroughly.  
Fluorescence was measured immediately in a 200 µL quartz microcuvette.  
MDCC was excited at a wavelength of 419 nm, and fluorescence emission 
collected at 466 nm.  Instrument slit widths were set to 4 nm, step size was 0.5 
nm, integration time was 0.1 s.  Fluorescence at 466 nm was graphed versus 
glucose concentration and analyzed using GraphPad Prism 5.0 software.   
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 Measurement of Far- and Near-UV Circular Dichroism Spectra.  Far-UV and 
near-UV circular dichroism spectra were collected for tGRP1 and tGRP2 in both 
the presence and absence of glucose.  Briefly, protein concentration was 
determined according to the method by Greenfield et al.[156]  Proteins were 
dialyzed in CD buffer (10 mM phosphate, 0.2 mM CaCl2, pH 7.5).  Protein 
samples were prepared at a concentration of 0.2 mg/mL with and without the 
presence of 100 mM glucose in CD buffer for far-UV experiments and 1.0 mg/mL 
for near-UV experiments.  Blank solutions consisting of CD buffer were prepared 
with and without 100 mM glucose.  Spectra were collected using a Jasco J-810 
spectropolarimeter.   
For far-UV experiments, spectra were collected at room temperature from 
200-260 nm, the data pitch was set to 0.5 nm, scanning mode was set to 
continuous, scan speed was 20 nm/s, response was set to 8 s, bandwidth was 1 
nm, and accumulations was set to 3.  A quartz CD cuvette with a pathlength of 
0.1 cm was used.  Near-UV experiments were carried out at room temperature in 
a quartz cuvette with a 1.0 cm pathlength.  Scans were performed with the 
settings mentioned above, however the wavelength range was 250-350 nm.  
Data for corresponding blanks were subtracted from each sample, and the 
results were converted to molar ellipticity.  Spectra were created by plotting molar 
ellipticity versus wavelength using GraphPad Prism 5.0 software. 
Determination of Protein Thermal Stability.  The melting temperature of each 
of the tGRPs was determined by monitoring circular dichroism at a wavelength of 
222 nm.  Samples were prepared as described for the far-UV experiments.  
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Settings were the same as above.  The temperature range was set from 10-90 
°C at a slope of 2 °C/min.  Data were plotted versus temperature using 
GraphPad Prism 5.0 software and normalized with respect to the signal at 70 °C.  
 
RESULTS AND DISCUSSION 
The glucose binding protein has been studied extensively as a possible 
sensing component of future generation of devices for the continuous, real-time 
monitoring of glucose for the management of diabetes.[72, 89, 151, 154]  
However, it has been noted that the native form of the protein has a binding 
affinity in the micromolar range, which is too low to be useful at physiologically-
relevant glucose concentrations, which range from 2-20 millimolar.  By truncating 
the structure of GBP, we hypothesize that the resulting perturbation in the 
structure and folding of the protein will result in an altered affinity for glucose.  
Truncation, like random and site-directed mutagenesis, may alter the stability, 
folding, activity, and binding interactions of a protein.  It has been shown that 
truncated proteins can exhibit altered activity and binding affinities.[157, 158] 
 Previous work has determined the binding constant of native GBP for 
glucose to be 0.2 µM.[89]  To investigate the effect of truncating GBP on the 
binding affinity and stability of the protein, three truncated versions of GBP were 
engineered.  These three proteins, tGRP1, tGRP2, and tGRP3 consist of amino 
acids 14-296, 14-256, and 87-271, respectively, of native GBP (Figure 4.1).  In 
order to maintain activity toward glucose, selectivity against other sugar 
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molecules, and the ability to undergo the correct conformational change, the 
native structure was truncated in such a way that most of the amino acids 
involved in hydrogen-bonding interactions within the binding site were 
maintained.  Native GBP interacts with glucose through a network of hydrogen-
bonding interactions involving Asp14, Asn91, His152, Asp154, Arg158, Asn211, 
Asp236, and Asn256 (Figure 4.1).[159]  tGRP1 and tGRP2 were engineered to 
include all amino acids listed above.  tGRP1 included all amino acids through 
residue 296 in order to maintain all three strands of the hinge region of the 
protein structure.  In the design of tGRP2, all amino acids located after residue 
256 were removed, thus maintaining all hydrogen-bonding amino acids as well 
as two of the three strands composing the hinge region.  In the design of tGRP3, 
much of one lobe of the protein, one strand of the hinge region, and one amino 
acid from the binding pocket were removed.  The three different proteins were 
expressed in E. coli and chemically modified via site-selective labeling of a 
unique Cys residue with a fluorescent coumarin probe, namely MDCC. 
 The truncated proteins were characterized in terms of their binding ability 
to glucose and to other sugers. Upon glucose binding, the fluorescence emission 
from the MDCC-labeled tGRPs was quenched.  We hypothesize that in the 
absence of glucose (when the protein structure is more open) the fluorescent 
probe MDCC assumes a position within the glucose binding pocket.  However, 
when glucose binds, MDCC is displaced from this position causing a change in 
fluorescence.  Native GBP exhibits a KD of 0.2 µM.  It was found that as the 
protein was increasingly truncated, the apparent KD increased, indicating a 
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decreasing affinity for glucose (Figure 4.1) to the point that tGRP3 showed no 
response to glucose (data not shown). In the structure of native GBP, eight 
amino acids are directly involved in hydrogen-bonding as a first-shell type of 
interaction with glucose, and, in addition, ten more amino acids interact with the 
first-shell amino acids to stabilize their structure around the sugar ligand.[159]  
While both tGRP1 and tGRP2 maintain all of the first-shell interacting amino 
acids, part of their second-shell amino acids was removed.  Specifically, in 
tGRP1 and tGRP2 one and four second-shell amino acids were removed 
respectively.  As more of these stabilizing, second-shell amino acids are 
removed, it is likely that the hydrogen-bonding interactions with glucose become 
disrupted, thus resulting in an increased KD of 75 µM for tGRP1 and 0.25 mM for 
tGRP2 (Figure 4.2).        
 Disrupting the first- and second-shell amino acids may also affect the 
selectivity of the proteins, causing them to respond to sugar molecules other than 
glucose and galactose.  As the overall structure becomes less stable, it is  
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Figure 4.2.  Normalized fluorescence response curve for tGRP1 and tGRP2.  
The glucose-response curve for tGRP1 and tGRP2 labeled at position 152 (with 
respect to native GBP) with MDCC.  MDCC-labeled protein was used at a final 
concentration of 1 x 10-7 M in buffer (10 mM HEPES, 0.2 mM CaCl2, pH 8.0).  
Glucose standards were prepared in buffer by serial dilution from a fresh 0.1 M 
glucose solution.  For the assay, 180 µL of the labeled protein solution was 
added to 20 µL of each standard, as well as a blank, in triplicate and mixed 
gently and thoroughly and fluorescence was measured immediately.  Data points 
represent the average of blank-subtracted triplicate samples.  The apparent KD 
for tGRP1 is 7.5 x 10-5 M and for tGRP2 is 2.5 x 10-4 M.  The dynamic range for 
tGRP1 and tGRP2 is 1 x 10-3 M – 1 x 10-6 M and 1 x 10-2 M – 1 x 10-5 M 
respectively.  Error bars denote +/- one standard deviation. 
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possible the binding pocket may become more flexible and able to accommodate 
other similarly-shaped ligands.  To investigate this, a selectivity study with 
MDCC-labeled tGRPs was carried out with a variety of physiologically-relevant 
sugar molecules (Figure 4.3).  As with native GBP, tGRPs responded best to 
glucose and to a lesser degree to galactose.  None of the other sugar molecules 
showed a significant response.   
To investigate whether the overall structural stability of the tGRPs was 
altered, the thermal stability of each tGRP was determined by circular dichroism 
(CD) spectroscopy.  Protein thermal stability is an important consideration when 
developing protein-based sensors that will be used for extended periods of time 
at human body temperatures. Improved thermal stability will increase the lifetime 
of the sensor allowing for long-term, reproducible glucose determination.  Native 
GBP has a melting temperature (Tm) of 66.9 °C in the absence of glucose and 
70.2 °C in the presence of glucose.[160]  Truncating the native structure had a 
significant effect on the thermal stability (Figure 4.4).  In the absence and 
presence of glucose, tGRP1 was found to have a Tm of 39.7 °C and 44.2 °C 
respectively.  The corresponding Tm values for tGRP2 were 37.3 °C and 43.2 °C.  
Since tGRP3 showed no glucose response, it was not characterized further.  This 
drastic loss in thermal stability indicates significant structural changes in the 
protein structure that result from truncation, which is manifested as an increase in 
dissociation constants for the ligand.   
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Figure 4.3.  Selectivity study of tGRP1 and tGRP2 with selected sugars.  
Samples for each sugar were prepared at a concentration of 100 mM in buffer 
and the experiment was carried out as described in Figure 1.  The total 
fluorescence signal is quenched approximately 80% by glucose and 40% from by 
galactose.  There was no significant response observed to maltose, sucrose, 
fructose, or lactose.  Error bars denote +/- one standard deviation. 
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Figure 4.4.  Thermal denaturation curves for tGRP1 (a.) and tGRP2 (b.) in 
the presence and absence of 100 mM glucose.  Proteins were prepared at a 
concentration of 0.2 mg/mL in CD buffer (10 mM phosphate, 0.2 mM CaCl2, pH 
7.5)  both in the absence of glucose and in the presence of 100 mM glucose.  CD 
was monitored at 222 nm as the temperature was increased from 10 to 70 °C at 
a rate of 2 °C per min. The melting temperature for tGRP1 was 39.7 °C in the 
absence of glucose and 44.2 °C in the presence of glucose.  The melting 
temperature for tGRP2 was 37.3 °C in the absence of glucose and 43.2 °C in the 
presence of glucose.  
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a. b.  
Figure 4.5.  Far-UV (a.) and near-UV (b.) CD absorbance of tGRP1 in the 
presence and absence of 100 mM glucose. 
Protein solutions and corresponding blanks were prepared at a concentration of 
0.2 mg/mL in CD buffer in the presence and absence of glucose as described in 
Figure 4.3.  The CD absorbance was measured from 260-200 nm at a pitch of 
0.5 nm in continuous scanning mode at a scan speed of 20 nm/s for far-UV and 
350-250 nm at a pitch of 0.5 nm and scan speed of 20 nm/min for near-UV 
measurements.  Three accumulations were averaged for each sample at room 
temperature.  The response for each blank was subtracted from the response for 
the corresponding sample and the resulting spectra are shown.characteristics of 
the proteins.   
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Further characterization of the tGRPs by circular dichroism revealed that, similar 
to native GBP, there was little change in the overall secondary structure.  This is 
evident from the far-UV CD absorbance spectra for tGRP1 and tGRP2 shown in 
Figures 4.5b and 4.6 a., respectively.  There is a slight change in the α-helix peak 
(approx. 210 nm and 220 nm) in the spectrum of tGRP1.  This may be due to a 
small change in the folding of the helices in the vicinity of the truncated portion of 
the sequence.   However, upon examining the individual spectra of the three data 
accumulations for each experiment, the differences may also be attributable to 
noise in the data.   
 The near-UV absorbance spectra (Figures 4.5 and 4.6 b) exhibit a small 
amount of change in the tertiary structure in the vicinity of the aromatic amino 
acids of the proteins upon glucose binding in the protein tGRP1.  This is 
observed in the near-UV CD absorbance spectra shown in Figure 5b.  The 
regions of the spectra which exhibit a slight difference correspond to 
phenylalanine (250-270) and tryptophan (280-300), while that corresponding to 
tyrosine (270-290) appears to remain unchanged.  This is consistent with the 
known models for the conformational change for native GBP.[161]  Examination 
of the local environments around these amino acids throughout the 
conformational change upon glucose binding gives some insight into the changes 
observed in the near-UV CD spectra.  In particular, there is both a tryptophan 
and a phenylalanine residue present within the binding pocket (Figure 4.7), and 
both of these amino acids seem to undergo a change in solvent exposure upon  
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a.  b.  
Figure 4.6.  Far-UV (a.) and near-UV (b.) CD absorbance of tGRP2 in the 
presence and absence of 100 mM glucose. 
Protein solutions and corresponding blanks were prepared at a concentration of 
0.2 mg/mL in CD buffer in the presence and absence of glucose as described in 
Figure 4.3.  The CD absorbance was measured from 260-200 nm at a pitch of 
0.5 nm in continuous scanning mode at a scan speed of 20 nm/sec for far-UV 
and 350-250 nm at a pitch of 0.5 nm and scan speed of 20 nm/min for near-UV 
measurements.  Three accumulations were averaged for each sample at room 
temperature.  The response for each blank was subtracted from the response for 
the corresponding sample and the resulting spectra are shown. 
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Figure 4.7.  Modeled structure near the binding pocket in the absence (a.) 
and presence (b.) of glucose.  The structures above were modeled using 
Discovery Studio 3.0 and coordinates provided in protein data bank (PDB) files 
2FW0 and 2FVY, respectively.  The tryptophan near the binding pocket is 
colored yellow, and the phenylalanine is colored orange.  
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glucose binding.  None of the other aromatic amino acids undergo such a 
noticeable change upon ligand binding. 
 
CONCLUSION 
 In conclusion, we present here a biosensor based upon truncated forms of 
GBP from E. coli.  Previous work has shown full-length GBP to have a binding 
constant in the micromolar range, which is too low for the development of a 
glucose biosensing system at physiologically relevant concentrations.  The 
apparent binding constant of the truncated proteins is shifted from the micromolar 
range, allowing for glucose determination in the physiologically relevant range.    
However, truncation of GBP also resulted in a decrease in thermal stability, 
decreasing the melting temperature for the protein when compared to its native 
form.  Ongoing work in our laboratory aims to modify GBP through the 
incorporation of unnatural amino acids, which may further modify properties of 
the protein such as the binding constant and thermal stability.  Additionally, the 
development of glucose recognition proteins based upon template proteins from 
thermophillic organisms should also yield more thermostable proteins. 
 
 
 
Copyright © Kendrick Bruce Turner 2011 
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CHAPTER FIVE 
DESIGN AND CHARACTERIZATION OF A GLUCOSE BIOSENSOR BASED 
ON THE INTRINSIC FLUORESCENCE OF A TRUNCATED, THERMOSTABLE 
GLUCOSE RECOGNITION PEPTIDE 
 
INTRODUCTION 
The World Health Organization and others project that by 2050, as many 
as one-third of Americans may suffer from diabetes.[162]  Among the 
contributing factors to this projection are poor lifestyle habits of the population, an 
aging population, and the increasing prevalence of other medical conditions as 
risk factors for diabetes.  As a result of this worsening epidemic, a need exists for 
reliable technologies to monitor the physiological concentration of glucose in 
order to effectively manage the disease.  Current-generation glucose monitoring 
systems rely on electrochemical methods for glucose detection, typically 
employing the enzyme glucose oxidase (GOx) in a mediator-based 
electrochemical sensor.[96, 149]  Many of these devices are commercially 
available, both for single-point blood glucose measurement and for continuous 
glucose monitoring in interstitial fluid.  While they have been very successful 
devices, they do suffer from some limitations.  Among these limitations are 
interference from other electrochemically active molecules, oxygen-dependence, 
and poor performance in the hypoglycemic range.[96, 150] 
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As an alternative to electrochemical-based detection methods, various 
optical methods have been pursued for the detection of glucose in biological 
fluids.[72, 163]  Among these are reagentless biosensing systems based on the 
binding ability of fluorescently-labeled glucose/galactose binding protein (GBP) 
from E. coli to glucose.[89]  GBP is a well-characterized protein first identified in 
E. coli, which binds glucose in a binding cleft located between two lobes that are 
connected by a flexible hinge region consisting of three strands with random coil 
secondary structure.  This binding results in a significant conformational change 
of the overall protein, bringing together the lobes by 8.5 Å.[159]  By attaching 
environmentally-sensitive fluorophores to the protein, a change in the 
fluorescence signal corresponding to the glucose concentration can be observed.  
Extensive research in modifying native GBP and site-specifically attaching 
various fluorophores to it has resulted in the development of proteins capable of 
sensitive, reproducible detection of glucose at concentrations approaching those 
in the physiological range.[151, 153] 
While work in the development of these fluorescent glucose biosensing 
systems has been ongoing for many years, no commercially-available sensing 
device has yet been developed.  One factor limiting the development of a 
fluorescence-based glucose-sensing device is that the labeled GBP needs to 
remain stable for extended periods of time.  To that end, the identification of 
GBPs from thermophilic organisms such as Pyrococcus horikoshii[164], Thermus 
thermophilus[165], and Thermotoga maritima[166] has opened new avenues for 
the development of more rugged, long-lived biosensing systems for glucose.  
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Proteins isolated from thermophilic organisms are remarkably stable with respect 
to extreme temperature, ionic strength, pH, and presence of chaotropic 
chemicals making them ideal for the development of biosensing systems that 
must be able to detect their target analyte in a sensitive and reproducible manner 
over long periods of time.[167] 
In this work, we report the design and characterization of a glucose 
recognition peptide, tmGRP4, based upon a truncated form of the glucose 
binding protein (tmGBP) from the microorganism Thermotoga maritima (Figure 
5.1).  Previously, it has been shown that full-length tmGRP site-specifically 
labeled at various locations with a fluorophore is capable of detecting glucose 
with binding affinities ranging from 12.7 nM to 147.7 mM.[166]  By studying 
truncated portions of the protein, we hypothesize that we can gain insights into 
the activity of the protein and identify portions that are required for ligand binding.  
This information will contribute to the further improvement and customization of 
the protein and the development of a minimized protein structure.  Herein, we 
demonstrate the feasibility of using the intrinsic fluorescence of a truncated form 
of the protein resulting from a single tryptophan residue present in the protein’s 
binding pocket as a means of detecting and quantifying glucose, thus eliminating 
the need for separate protein modification steps.  Additionally, by monitoring 
changes in intrinsic fluorescence, we have been able to characterize the protein 
with respect to binding affinity and selectivity without perturbations in its 
structure, a potential drawback when proteins are modified with a fluorophore in 
a location near the binding pocket. 
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EXPERIMENTAL PROCEDURES 
Reagents.  Oligonucleotide primers were purchased from Operon 
Biotechnologies (Huntsville, AL).  Thermotoga maritima genomic DNA was 
purchased from ATCC (Manassas, VA).  Ampicillin, chloramphenicol, glucose, 
sodium ascorbate, D(+)-raffinose, cholesterol, D-Lyxose, L(+)-arabinose, D(+)-
maltose, lactose, 2-amino-2-hydroxymethyl-propane-1,3-diol (tris base), β-
mercaptoethanol, and agarose were purchased from Sigma (St. Louis, MO).  
Luria-Bertani (LB) broth and agar, sodium chloride, sucrose, sodium phosphate 
monobasic, sodium phosphate dibasic and glycine were purchased from Fisher 
Scientific (Fair Lawn, NJ).  Restriction enzymes XhoI and BamHI and T4 DNA 
ligase were purchased from Promega (Madison, WI).  Ni-NTA agarose resin, 
QIAquick gel purification kit, and QIAprep DNA isolation kit were purchased from 
Qiagen (Valencia, CA).  QuickChange II site-directed mutagenesis kit and 
pfuUltraII DNA polymerase were purchased from Stratagene (La Jolla, CA).  
Imidazole and guanidine hydrochloride were purchased from J.T. Baker 
(Phillipsburg, NJ).  D(+)-galactose was purchased from Acros Organics (Geel, 
Belgium).  Sodium dodecyl sulfate (SDS) was purchased from Curtin Matheson 
(Houston, TX).  Tris(2-carboxyethyl)phosphine (TCEP) and Rosetta 2 (DE3) cells 
were purchased from EMD (Gibbstown, NJ).  Isopropyl β-D-1-
thiogalactopyranoside (IPTG) was purchased from Gold Biotechnology (St. 
Louis, MO).  TOP10F’ cells were purchased from Invitrogen (Carlsbad, CA).  The 
vector pET21a(+) was purchased from Novagen (Darmstadt, Germany).  D(+)-
fructose was purchased from Spectrum (Gardena, CA).   
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Apparatus.  Polymerase chain reactions (PCR) were performed using an 
Eppendorf Mastercycler Personal Thermocycler (Hauppauge, NY). 
Electrophoresis of DNA was carried out using an FB105 Fischer Biotech 
Electrophoresis Power Supply (Pittsburg, PA).  DNA gels were visualized using a 
UV Transilluminator platform from UVP (Upland, CA).  Optical density 
measurements were taken using a Spectronic 21D from Milton Roy (Ivy Land, 
PA).  Cells were lysed using a 550 Sonic Dismembrator from Fisher Scientific 
(Pittsburg, PA). Cell cultures were grown by incubating bacteria in a Forma 
Scientific Orbital Shaker (Fairlawn, NJ).  All centrifugations were carried out 
using a Beckman J2MI centrifuge (Palo Alto, CA).  Proteins were visualized by 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) using 
Mini-PROTEAN TGX 4-20% SDS-PAGE gels purchased from Bio-Rad 
(Hercules, CA).  Fluorescence measurements were obtained using a 
QuantaMaster 40 Spectrofluorometer from PTI (Birmingham, NJ).  Circular 
dichroism experiments were performed using a BioLogic MOS 450/PMS 450 
Spectrometer from BioLogic (Claix, France). 
Cloning of Glucose Recognition Peptides (tGRPs) into Expression Plasmid.  
The gene for GBP from T. maritima was isolated by PCR from purchased 
genomic DNA using the primers tmGRP-21aXhoI (5’-
GGTGGTCTCGAGGAATTTTATTGGAATTCCG-3’) and tmGRP-21aBamHI (5’-
GGTGGTGGATCCCTCACCATAGGTGTTATCGG-3’) with the restriction sites 
XhoI and BamHI underlined, respectively.  The PCR reaction was carried out 
using pfuUltraII DNA polymerase with an initial denaturation of 95 °C for 2 min.  
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Next, 30 cycles of a denaturation step at 95 °C for 30 s, and annealing step at 63 
°C for 20 s, and an elongation step at 72 °C for 30 s were carried out.  A final 
elongation step of 72 °C for 3 min completed the PCR reaction.  The resulting 
products were analyzed by agarose gel electrophoresis for correct size and 
purity, and the appropriately sized band (915 bp) was excised from the gel and 
purified using the QIAquick gel extraction kit. 
 Following PCR product purification, the product along with the expression 
vector pET21a(+) were digested with restriction enzymes XhoI and BamHI.  
Digestion was carried out per instructions provided with the restriction enzymes.  
Following digestion, the products were analyzed by agarose gel electrophoresis.  
Next, a gel slice of digested PCR product was combined with a gel slice of 
digested expression vector and co-purified using the QIAquick gel extraction kit.  
To the purified DNA, T4 ligase and T4 ligase buffer (10x) were added, and the 
ligation reaction was allowed to complete overnight at room temperature.  The 
resulting ligated DNA was transformed into TOP10F’ cells following standard 
transformation procedures.  Colonies resulting from the transformation were 
analyzed for the presence of the correct insert by overnight growth in LB media 
supplemented with ampicillin (100 µg/mL) and digestion of the purified DNA with 
restriction enzymes XhoI and BamHI as above.  Glycerol stocks were made of 
those colonies which appeared correct, and the isolated plasmid, tmGRP-
pET21a(+), was sent for DNA sequencing for confirmation. 
 In order to introduce a cysteine at position 135, site-directed mutagenesis 
was carried out using the QuickChange II site-directed mutagenesis kit.  The 
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mutagenesis primers used were tmGRP-mut-135A/C (5’-
ACGGGTTCACTGACATGTATGAACTCCCTTCAG-3’) and tmGRP-135A/C-rev 
(5’-CTGAAGGGAGTTCATACATGTCAGTGAACCCGA-3’).  The reaction mixture 
was prepared per the kit instructions.  An initial denaturation step was performed 
at 95 °C for 30 s.  Following this, 30 cycles of a denaturation step at 95 °C for 30 
s, an annealing step of 55 °C for 1 min, and an elongation step of 68 °C for 5 min 
were completed.  A final elongation step was performed at 68 °C for 5 min.  The 
resulting products were analyzed for purity and correct size by agarose gel 
electrophoresis.  The resulting mutated plasmid was transformed into TOP10F’ 
cells following standard transformation protocols.  Following the transformation, 
colonies were analyzed for the presence of the correct plasmid by growth 
overnight in LB broth supplemented with ampicillin (100 µg/mL).  From the 
overnight cultures, the plasmid DNA was isolated and digested as above with 
XhoI and BamHI and analyzed by agarose gel electrophoresis to confirm the 
presence of the insert and expression vector bands.  Glycerol stocks were 
prepared of appropriate colonies, and the isolated plasmid, tmGRP135C-
pET21a(+), was sent for DNA sequencing for confirmation. 
 For the preparation of truncated glucose binding proteins from T. maritima 
(tmGRP4), PCR was performed using the above prepared plasmid, tmGRP135C-
pET21a(+), as template DNA.  The final truncated proteins were designed to 
consist of amino acids 14-254 (tGRP4), 14-206 (tGRP5) and 1-254 (tGRP6) of 
the native protein.  A PCR reaction was carried out for truncation of the 
tmGRP135 gene using the primers tmGRP4-fwd-BamHI (5’-
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GGTGGTGGATCCTACTGGTCACAGGTAGAACAAGGT-3’) and tmGRP4-rev-
XhoI (5’-GGTGGTCTCGAGCTTGTTCATCAGATAAAGAACTGT-3’) for the 
amplification of tGRP4, the primers tmGRP4-fwd-BamHI and tmGRP5-rev-XhoI 
(5’-GGTGGTCTCGAGTTTTCCAGCATTTTTCACCACGAG-3’) for the 
amplification of tGRP5, and the primers tmGRP6-fwd-BamHI (5’-
GGTGGTGGATCCCTCCACCATAGGTGTTATCGGAAAA-3’) and tGRP4-rev-
XhoI for the amplification of tGRP6.  PCR reaction parameters were identical as 
above for the preparation of tmGRP-pET21a(+).  Following the PCR reaction, the 
products were analyzed by agarose gel electrophoresis.  DNA bands for tGRP4 
(723 bp), tGRP5 (579 bp), and tGRP6 (759 bp) were excised and purified using 
the QIAquick kit.  After DNA isolation, each product, along with expression vector 
pET21a(+) were digested with restriction enzymes XhoI and BamHI as above.  
The digested DNA was purified by agarose gel electrophoresis, and the 
appropriate DNA bands were excised from the gel.  In separate tubes, excised 
DNA of each truncated product was combined with excised DNA for the 
expression vector, and co-purified using the QIAquick kit.  To the purified DNA, 
T4 DNA ligase and T4 ligase buffer (10x) were added, and the ligation reaction 
was incubated overnight at room temperature.  After ligation, the resulting 
plasmids, tGRP4-pET21a(+), tGRP5-pET21a(+), and tGRP6-pET21a(+) were 
transformed into Rosetta2(DE3) cells for protein expression.  Colonies from 
these transformations were grown overnight in LB broth supplemented with 
ampicillin (100 µg/mL) and chloramphenicol (25 µg/mL), preserved as glycerol 
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stocks, and plasmid DNA was isolated as before and sent for sequencing for 
confirmation. 
Recombinant Protein Expression and Purification.  For the expression of 
tGRP4, an overnight culture of tGRP4-pET21a(+) in Rosetta2(DE3) was grown in 
LB media supplemented with ampicillin (100 µg/mL) and chloramphenicol (25 
µg/mL).  The following day, expression cultures were grown (2 x 500 mL) in LB 
broth supplemented with ampicillin (100 µg/mL) and chloramphenicol (25 µg/mL) 
at 37 °C to an OD600 of approximately 0.5.  Protein expression was induced by 
the addition of IPTG to a final concentration of 1.0 mM, and the culture was 
grown overnight at 37 °C. 
 In order to harvest the cells after protein expression, the culture was 
centrifuged at 12,000 x g, at 4 °C, for 20 min.  Cells were resuspended in lysis 
buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0) and lysed by 
pulsed sonication (10 s on, 10 s off, 10 min total sonication).  Following cell lysis, 
the lysate was centrifuged at 12,000 x g, at 4 °C, for 20 min, to remove debris.  
The supernatant was transferred to a fresh centrifuge tube, 1.0 mL of Ni-NTA 
agarose resin was added, and the solution was incubated at 4 °C for 1 h.  The 
solution was then applied to a gravity-flow column, and the flow-through fraction 
was collected.  The resin was then washed with 10 mL of wash buffer 1 (50 mM 
NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH 8.0), then 3 mL of wash buffer 2 
(50 mM NaH2PO4, 300 mM NaCl, 50 mM imidazole, pH 8.0), and finally 3 mL of 
wash buffer 3 (50 mM NaH2PO4, 300 mM NaCl, 100 mM imidazole, pH 8.0).  The 
wash fractions were collected in separate tubes.  Finally, the protein was eluted 
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from the column in six 1.0 mL fractions of elution buffer (50 mM NaH2PO4, 300 
mM NaCl, 250 mM imidazole, pH 8.0).  Following purification, the products were 
analyzed for purity by SDS-PAGE.  Elution fractions containing purified protein 
were combined in an amber glass vial and stored at 4 °C.  Protein concentrations 
were determined using method A detailed by Greenfield et al.[156] 
Fluorescence Measurements of GRPs.  All fluorescence measurements were 
carried out in assay buffer (20 mM phosphate, 20 mM NaCl, 1.0 mM TCEP, pH 
7.0) at a protein concentration of 1.0 x 10-6 M.  Glucose standards were prepared 
in assay buffer and stored at 4 °C.  Tryptophan fluorescence was excited at 278 
nm and emission was measured at 340 nm.  For excitation and emission scans, 
instrument settings were as follows:  excitation and emission slit widths were set 
at 1 nm and 3 nm respectively, monochromator step size was set at 0.5 nm, 
integration time was 0.5 s, 3 scans were averaged for each acquisition.  For 
glucose assays, a time-based acquisition program was established with the 
same excitation and emission wavelengths as above, and fluorescence intensity 
was averaged over 2.5 s with a single reading every 0.5 s.  Apparent binding 
constants were determined using the statistical analysis software GraphPad 5.0.  
Briefly, the fluorescence intensity was plotted versus glucose concentration and a 
sigmoidal response curve was fitted to the data following Equation 1: 
	 	 	 	  Equation 1 
In Equation 1, the values for Top and Bottom are determined by the plateau 
regions resulting from the highest and lowest concentration data points, 
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respectively.  The Hill slope is variable and dependent upon the slope along the 
curve calculated about each data point.  The logEC50 is the logarithm of the 
concentration that results in a change in signal halfway between the Top and 
Bottom values, or when half of the protein binding sites are occupied.  For this 
reason, the apparent binding constant can be derived from the logEC50 value. 
Determination of Protein Thermal Stability.  Protein thermal stability was 
investigated by the measurement in intrinsic tryptophan fluorescence as a 
function of temperature and the concentration of the chaotropic agent guanidine 
hydrochloride.  Briefly, the same protein concentration was used for each 
experiment.  The instrument settings were also kept the same as described 
above.  Fluorescence was measured at the wavelengths used above throughout 
a temperature ramp from 20 °C to 90 °C at a rate of 5 °C per minute with stirring.  
An initial hold time of 180 s at 20 °C was used prior to the temperature ramp, and 
the linear decay of fluorescence was extrapolated throughout the total 
experiment time and subtracted from the temperature ramp fluorescence curve in 
order to account for the effects of photobleaching throughout the experiment.  
Samples were measured both in the absence of glucose, and with a glucose 
concentration of 1.0 M.  Additionally, the concentration of guanidine 
hydrochloride was varied from 0.0 M to 4.5 M. 
Measurement of Far- and Near-UV Circular Dichroism (CD) Spectra.  To 
investigate protein conformational changes upon glucose binding, both far- and 
near-UV circular dichroism spectra were measured.  For far-UV CD, the proteins 
were evaluated at a concentration of 0.2 mg/mL in CD buffer (20 mM phosphate, 
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20 mM NaCl, pH 7.0) in a quartz cuvette with a pathlength of 1.0 mm.  Instrument 
settings were as follows:  wavelength range was 180-260 nm, scan repeat was 4, 
acquisition duration was 20 s, and shutter mode was always open.  Samples 
were measured in the absence of glucose, and with a glucose concentration of 
100 mM.  Corresponding blanks were measured with the same glucose 
concentrations in buffer, with no protein present, and subtracted from the protein 
CD data.  For near-UV CD, the proteins were evaluated at a concentration of 1.0 
mg/mL in CD buffer in a quartz cuvette with a pathlength of 1.0 cm.  Instrument 
settings and sample preparation were as above for far-UV CD, except the 
wavelength range was 250-350 nm.  
Determination of Protein Specificity.  Protein specificity was determined for 
selected analytes.  Sample solutions of protein in assay buffer were prepared in 
a similar manner as for glucose assays.  To these protein solutions, the selected 
analytes were added, in triplicate, and the fluorescence intensity was measured.  
Analytes were added to the protein solution at a final concentration of 1.0 mM 
with the exception of cholesterol, and ascorbate, which were added at a final 
concentration of 10 and 50 µM, respectively. 
 
RESULTS AND DISCUSSION 
 In this work, we report the design of a truncated form of the glucose 
binding protein from Thermotoga maritima.  By studying truncated versions of the 
full-length protein, we have gained some insight into portions of the protein which 
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are necessary for proper folding and activity.  Specifically, it was observed that 
tGRP5, which lacks 113 out of 305 amino acids of full-length tmGRP was unable 
to properly fold and/or respond to glucose (data not shown).  However tGRP4, 
which lacks 65 amino acids, maintains a response to glucose.  This suggests that 
some of the amino acids removed in tGRP5 must be essential for protein folding 
and glucose interaction.  Previously published strategies for engineering glucose 
binding proteins to elicit an optical response have relied on fusion with a suitable 
bioluminescent or fluorescent reporter protein[72, 168] or the site-specific 
incorporation of a cysteine residue and subsequent covalent attachment of 
environmentally-sensitive organic fluorophores.[89, 151]    The engineered 
protein in this work, tGRP4, contains a single tryptophan residue that resides in 
the binding cavity of the protein and interacts directly with glucose through a 
hydrogen bonding interaction (figure 5.1).  When tGRP4 is bound to glucose, this 
tryptophan shows a concentration-dependent enhancement of intrinsic 
tryptophan fluorescence resulting in a total fluorescence enhancement of 
approximately 9% at maximum signal intensity and an apparent binding constant 
of 3.0 x 10-6 (figure 5.2).  Continuous, time-based measurements of tGRP4 in 
solution also showed that the total change in fluorescence is observed within 5 s 
of the addition of glucose (data not shown).   
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Figure 5.2. Calibration curve of tGRP4 in response to glucose.  The percent 
enhancement of the intrinsic tryptophan fluorescence intensity with respect to 
glucose concentration is shown above.  tGRP4 was added to 2.0 mL of assay 
buffer at a final concentration of 1.0 x 10-6 M in a quartz cuvette with a path 
length of 1 cm.  Glucose was added from standard solutions in aliquots of 0.5 µM 
resulting in the final concentrations above.  Data represent an average of 3 
replicate measurements with standard deviations depicted with error bars (some 
error bars obscured by datap points.  A sigmoidal-response curve was fitted 
using GraphPad Prism 5.0 software, and an apparent binding constant of 3.0 x 
10-6 M was calculated based on the curve. 
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 Previously developed biosensors based on GBP from E. coli have been 
shown to respond to galactose as well as glucose with a slightly higher binding 
affinity latter.[89]  Work in our laboratory has demonstrated that truncating the 
native protein structure for GBP from E. coli alters the binding affinity and 
response of the protein.  To investigate whether the selectivity of tGRP4 is 
altered compared to full-length tmGBP, we measured the response of the protein 
to several other sugars as well as cholesterol and ascorbate, which have been 
shown to act as interfering species in electrochemically-based glucose sensors.  
The compounds were investigated at the following concentrations:  ascorbate 
was added at a concentration of 50 µM, cholesterol was added at a concentration 
of 10 µM, and all sugars were added at a concentration of 1 mM. As shown in 
figure 5.3, the addition of maltose, a disaccharide of glucose, results in an 
enhancement of fluorescence that is indistinguishable from glucose.  However, 
physiologically, maltose is rapidly metabolized to glucose.  Additionally, there is a 
significant quenching in fluorescence resulting from the addition of ascorbate.  
This quenching effect is also observed in solutions of tryptophan (data not 
shown) indicating that the effect is not due to the binding of ascorbate to the 
protein, but rather to quenching of tryptophan fluorescence by ascorbic acid. 
 To investigate this effect, we performed experiments to determine the 
effects of various physiologically-relevant concentrations of ascorbic acid on the 
response of the protein (Figure 5.4).  Indeed, as the concentration of ascorbic 
acid was increased, the raw fluorescence measured decreased.  However, it was 
observed that the addition of glucose still resulted in fluorescence enhancement,  
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Figure 5.3. Selectivity study of tGRP4. Each compound was added at a final 
concentration of 1.0 mM in triplicate, except ascorbate which was added at 50 
µM and cholesterol, which was added at 10 µM.  The response of maltose was 
indistinguishable from that of glucose, and ascorbate demonstrated a dramatic 
quenching effect of tryptophan fluorescence at the concentration above. 
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Figure 5.4.  Glucose calibration curves in the presence of ascorbate.  
Glucose assays were performed at 0 µM (▼), 10 µM (●), and 100 µM (■) of 
ascorbate.  While the percent enhancement of tryptophan fluorescence was 
maintained, the raw signal was decreased as the concentration of ascorbate was 
increased.  Data represent an average of 3 replicate measurements with 
standard deviations depicted with error bars (some error bars obscured by data 
points).  A sigmoidal-response curve was fitted using GraphPad Prism 5.0 
software,  
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and the percent enhancement of fluorescence was virtually identical to that 
observed in the absence of ascorbic acid.  Because of this, it is believed that a 
biosensing system which employs the intrinsic fluorescence of tGRP4 would still 
be feasible if a standard addition approach was used to eliminate the interference 
from ascorbic acid.   
 In the development of a commercially-viable device, an important 
parameter for any blood glucose monitoring system is sensor lifetime, especially 
for continuous glucose monitors (CGMs).  Sensor lifetimes are limited by several 
factors, most prominently an immune response to the implanted sensor as a 
foreign body.[169]  There are only a few FDA-approved CGMs currently on the 
market, and most of these have sensor lifetimes of 3-5 days, with the longest 
being 7 days.  To test the lifetime of tGRP4, we compared the response of fresh 
protein from storage at 4 °C to that of protein stored long-term at 37 °C.  The 
results of this study, shown in figure 5.5, reveal that virtually no loss in tGRP4 
activity is observed within 72 h.  The protein is still capable of glucose detection 
for as long as 5 days, albeit at a decreased response. 
 To further investigate the thermal stability of tGRP4, glucose assays were 
carried out at temperatures ranging from 37 °C to 60 °C (Figure 5.6).  The 
importance of protein stability to high temperatures related not just to 
physiological measurements, but also to transport and storage of proteins that  
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Figure 5.5. Effect of long-term storage at 37 °C on assay performance.  
Glucose assays were completed with protein solution fresh from storage at 4 ºC 
(●), and after protein storage at 37 °C for 24 h (■), 48 h (▲), 72 h (■), 96 h (▼), 
120 h (♦), and 168 h (+).  Protein activity was maintained through 72 h, at which 
time the percent fluorescence enhancement began to decrease.  No glucose 
response was observed beyond 120 h.  Data represent an average of 3 replicate 
measurements with standard deviations depicted with error bars (some error 
bars may be obscured by data points).  A sigmoidal-response curve was fitted 
using GraphPad Prism 5.0 software, 
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Figure 5.6. Effect of temperature on glucose response.  Glucose assays were 
performed at 37 ºC (●), 44 ºC (■), 50 ºC (▼), and 60 ºC (♦).  Data represent an 
average of 3 replicate measurements with standard deviations depicted with 
error bars (some error bars may be obscured by data points).  A sigmoidal-
response curve was fitted using GraphPad Prism 5.0 software. 
  
134 
 
need to be used in devices and as diagnostic tools.  Proteins with improved 
thermal stability tend to have increased tolerance to elevated temperatures 
during measurement and improved shelf-life at non-ideal storage and transport 
conditions (i.e., tropical or desert environments).  This improved tolerance 
reduces the need for special storage conditions, making devices based upon 
these proteins more amenable to use in extreme environments.  As expected for 
a thermostable protein, activity was maintained at higher temperatures.  As the 
temperature was increased further to 60 °C, the response curve was shifted to an 
increased apparent binding affinity of 2.6 x 10-4 M.  For a thermostable protein, it 
would be expected that binding would be stronger at a higher temperature.  This 
observed shift in binding affinity is likely the result of a decreased rigidity in the 
protein structure of the truncated protein as compared to the full-length protein.  
As the overall flexibility of the protein structure is increased, the binding of 
glucose within the binding cavity likely becomes less favorable.  As the 
temperature increased, a decrease in absolute fluorescence intensity was also 
observed.  This can likely be attributed to increased collisional quenching as the 
flexibility of the protein is increased and the exposure of tryptophan to the solvent 
increases. 
 The stability of the protein structure was further explored by measuring the 
fluorescence intensity of the tryptophan residue as the temperature was 
increased from room temperature to 90 °C in the presence of the chaotropic 
agent, guanidine hydrochloride.  Guanidine was added to shift the melting 
transition of the protein to a temperature that is experimentally relevant, since the 
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protein in the absence of chaotropic agents has a melting temperature well 
above the boiling point of water.  As mentioned above, tGRP4 contains a single 
tryptophan residue located within the binding cavity, in the hydrophobic interior of 
the protein.  As chemical and thermal stresses are placed on the protein, its 
secondary and tertiary structural features should begin to unravel as the protein 
denatures. This should result in the buried tryptophan residue becoming more 
exposed to the aqueous environment surrounding the protein, and a decrease in 
measured intrinsic tryptophan fluorescence.  It has also been previously shown 
that the presence of glucose contributes to an increased stability of the protein 
structure of GBPs, resulting in an increase in thermal- and chemical- 
stability.[160, 166]  Figure 5.7 shows the normalized tryptophan fluorescence as 
a function of temperature with various concentrations of guanidine present.  As 
shown in figure 5.7a, the melting transition is observed to begin around 70 °C in 
the absence of glucose and around 80 °C in the presence of glucose at a 
guanidine concentration of 1.0 M, and the protein never reaches a completely 
unfolded state, as indicated by the continuous decrease in fluorescence.  At 3.0 
M guanidine (figure 5.7b), the protein begins to unfold at a temperature just 
above 40 °C in the absence of glucose, and begins to reach a completely 
unfolded state at around 70 °C.  In the presence of glucose, protein structure is 
maintained and the melting transition is again observed to begin at approximately 
80 °C.  Finally, at a concentration of 4.5 M guanidine (figure 5.7c) and in the 
absence of glucose, the melting transition begins just above 20 °C, indicating a 
highly denaturing environment, however, denaturation is still incomplete until a  
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a. b.  
c.  
Figure 5.7. Thermal and chemical denaturation of tGRP4. Assay solutions 
were prepared in the absence and presence of glucose with various 
concentrations of guanidine hydrochloride (Guan).  While measuring tryptophan 
fluorescence, the temperature was ramped from 20-90 °C.  Protein melting was 
observed as the tryptophan fluorescence is quenched.  As the concentration of 
guanidine was increased, the melting transition shifted to lower temperatures.  As 
shown by the increased melting transition temperatures, the presence of glucose 
increased the stability of the protein structure. 
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temperature of approximately 75 °C.  In the presence of glucose at this guanidine 
concentration, denaturation does not begin until approximately 60 °C, and the 
protein is not completely disordered until over 80 °C. 
 In order to investigate the conformational change which occurs in tGRP4 
upon glucose binding, the far- and near-UV CD spectra were measured in the 
absence and presence of glucose.  As shown in figure 5.8a, the far-UV CD 
spectrum, which reveals changes in protein secondary structure, showed little 
change in response to glucose.  This is consistent with available structural data 
for full-length tmGBP.  Near-UV spectra, on the other hand, provides information 
on changes in the tertiary structure in the environment around the aromatic 
amino acids phenylalanine (250-270 nm), tyrosine (270-290 nm), and tryptophan 
(280-300 nm).  As shown in figure 5.8b, there is a broad peak centered around 
275 nm that is somewhat increased in the presence of glucose.  This is likely 
attributed to a tyrosine located on the edge of the binding pocket that is believed 
to experience a change in solvent exposure as a result of the conformational 
change. 
 
CONCLUSION 
 In this work, we have developed a glucose biosensor using a thermally 
stable protein, tGRP4, which is based on a truncated form of GBP from the 
hyperthermophilic organism, Thermotoga maritima.  Many previous glucose  
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a.  
b.  
Figure 5.8. Far-UV (a.) and near-UV (b.)CD absorbance of tGRP4 in the 
presence and absence of 100 mM glucose.  Protein solutions and 
corresponding blanks were prepared at a concentration of 0.2 mg/mL in CD 
buffer containing 0 mM (---) or 100 mM (—) glucose as described in figure 5.3.  
The CD absorbance was measured from 200-260 nm for far-UV and 250-350 nm 
for near-UV measurements.  Four accumulations were averaged for each sample 
at room temperature.  The response for each blank was subtracted from the 
response for the corresponding sample and the resulting spectra are shown. 
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biosensing systems based on glucose binding proteins rely on the covalent 
attachment of a small fluorophore to a specific position within the protein 
structure.  The work presented herein instead relies on the intrinsic fluorescence 
of a tryptophan residue located within the binding cavity of the protein, negating 
the time and expense of the extra labeling steps required for fluorophore-labeled 
proteins.  This approach could be applied to other protein-based sensing 
systems through the introduction of a unique tryptophan within a protein’s 
structure. We have shown that tmGRP can withstand the removal of 65 amino 
acids (over 20% of the total protein) while still maintaining binding activity.  This 
provides insight into developing a minimized protein structure, which may be 
more amenable to customizability.  We have also demonstrated several desirable 
properties of a CGM system such as a sensor lifetime on the order of 3-5 days, 
maintained sensor performance under extreme conditions, and accurate 
detection of glucose which was both reproducible, and selective. The improved 
thermal stability gained from using a hyperthermophilic variant of GBP provides 
the advantages of a rugged protein that is more tolerable of extreme conditions 
such as temperature both during use in a biosensing system as well as during 
storage and transport.  We envision that integration of the engineered protein into 
a fiber-optic based biosensing system will result in the design and development 
of long-lived practical optical glucose monitoring platforms and devices capable 
of performance at physiological temperatures and pH, and that are selective to 
glucose over a wide variety of sugars.   
Copyright © Kendrick Bruce Turner 2011 
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CHAPTER SIX 
 
CONCLUSIONS AND FUTURE PERSPECTIVES 
 
 Nature has spent billions of years evolving mechanisms by which 
organisms can sense and respond selectively to stimuli in their surrounding 
environment.  This degree of adaptation has allowed organisms to identify and 
transport needed nutrients into cells, to remove waste products that would 
otherwise accumulate to toxic concentrations within cells, and to defend against 
exposure to harmful toxicants.  The biological sensing tools that nature has 
developed to accomplish these tasks have been discussed extensively in this 
dissertation and include regulatory proteins that recognize small effector 
molecules and trigger the expression of appropriate genes and chemotaxis 
proteins that actively transport small molecules into and out of cells.  It has been 
the goal of this work to exploit these naturally occurring biosensing systems and 
engineer them to serve as sensitive, selective, reproducible, and rugged systems 
which can be employed in the detection of small molecules of interest, including 
both biologically and physiologically relevant compounds.  Additionally, we have 
gained some insight into the relationship between the structure of the various 
sensing proteins studied and their relevant analytical response characteristics.   
 Chapter two presented a whole cell sensing system for hydroxylated 
polychlorinated biphenyls (OH-PCBs).  These compounds are metabolites of 
PCBs and can serve as a biomarker of PCB exposure.  By employing the 
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regulatory protein, HbpR, from the bacterium Pseudomonas azelaica, we were 
able to construct a biosensing system capable of detection OH-PCBs at 
concentrations down to the nanomolar range.  In this strategy, the expression of 
the reporter protein, bacterial luciferase, was put under the regulatory control of 
HbpR.  Chapter three presents a protein-based sensing system based upon 
HbpR.  In this work, the effector binding A-domain of HbpR (HbpR-A) was 
isolated and labeled at cysteines in the structure with an environmentally-
sensitive fluorophore, 5-[2-[(2-Iodo-1-oxoethyl)amino]ethylamino]-1-
naphthalenesulfonic acid (IAEDANS).  Upon analyte binding, likely due to a 
conformational change in HbpR-A, a change in the fluorescence intensity 
observed that could be correlated to OH-PCB concentration.  A limiting factor in 
the development of the protein-based biosensor was the lack of structural 
information available for HbpR.  Serendipitously, our protein was responsive to 
OH-PCBs when labeled with IAEDANS.  Determination of the three-dimensional 
structure of HbpR would allow a more rational approach to improving the 
response of the sensing system.  For instance, by replacing or removing any 
cysteines which are not affected by the conformational change, the background 
fluorescence could be reduced, which should result in improved detection limits.  
Additionally, identification of amino acids present in the binding pocket of the 
protein and elucidation of the specific interactions between these amino acids 
and the OH-PCBS should provide the opportunity to rationally alter these 
interactions to improve the selectivity of the protein which could eventually allow 
us to tailor the protein such that we can preferentially detect some OH-PCBs 
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(e.g., more highly-substituted congeners) over others.  Ongoing work by groups 
with greater expertise in protein structure determinations, especially the van der 
Meer group, is attempting to determine a structure for HbpR.  However, this class 
of regulatory proteins has presented much difficulty in expression and purification 
of isolated, full-length protein.  This has hindered the determination of the 
structure of HbpR. 
 In chapter four, truncated fragments of the extensively studied glucose 
binding protein (GBP) from E. coli were engineered to function as a biosensor for 
glucose.  Native GBP has been previously engineered such that a fluorophore, 7-
diethylamino-3-((((2-maleimidyl)ethyl)amino)carbonyl)coumarin (MDCC), was 
attached at a unique cysteine at position 152.  However, the full-length native 
protein has been found to have a binding affinity in the micromolar range.  In 
order to be useful in a sensing system for physiologically-relevant glucose 
concentrations, the binding affinity would need to be in the millimolar range.  To 
that end, we designed truncated glucose recognition peptides (tGRPs) based 
upon the template of full-length GBP.  We hypothesized that by truncating the 
native protein, we may be able to see a shift in the binding affinity, in addition to 
other changes in the characteristics of the protein.  Indeed, we observed that as 
the protein was truncated to a greater extent, the binding affinity shifted to higher 
concentrations of glucose.  However, truncating the native protein also 
demonstrated the negative effect of reducing the thermal stability of the protein, 
resulting in a melting temperature much lower than full-length GBP.  Preliminary 
work in our laboratory has circumvented this through the global incorporation of 
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fluorinated unnatural amino acid analogues that are known to increase the 
thermal stability in other proteins.  Additionally, by identifying portions of the 
protein that must be conserved to maintain a functional protein, we are moving 
toward a small enough protein that the possibility of constructing the protein 
using peptide synthesis methods may become a reality.  This would allow us 
greater control over customizing the protein by easily introducing site-specific 
mutations.  Additionally, the library of unnatural amino acids available for 
incorporation into the amino acid sequence is more extensive when using solid 
state protein synthesis.   
 The fifth chapter details the pursuit of another protein-based biosensor for 
glucose based upon the hyperthermophilic glucose binding protein (tmGBP) from 
the extremophil, Thermotoga maritima.  We chose this protein because of its 
exceptional thermal stability; in the presence of glucose the melting temperature 
of tmGBP is well over 100 °C.  Improved thermal stability should improve sensor 
lifetime and facilitate a more rugged sensor, which can perform in more extreme 
conditions and withstand a greater variety of storage and transport conditions.  
Again, in this work, we sought to develop truncated fragments of the full-length 
protein in an effort to realize a minimized protein structure that would afford all of 
the benefits mentioned previously.  This work also relied on the intrinsic 
fluorescence of a single tryptophan residue located within the binding pocket of 
the protein instead of an exogenous fluorophore.  The use of intrinsic protein 
fluorescence mitigates the need for extra labeling and purification steps. 
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 Future work for each of the protein-based sensing systems will also 
involve further alteration of the protein structures and, as a consequence, their 
response properties by incorporation of unnatural amino acid analogues.  This 
work is already ongoing in our laboratory with the incorporation of fluorinated 
tryptophans and leucines into GBP and the tGRPs discussed in chapter 4.  
Results thus far suggest that incorporating these fluorinated amino acids, 
especially the fluorinated leucine, increases the thermal stability of the protein.  
Other avenues of continued research in this vein include the incorporation of 
unnatural amino acids which can themselves be used as the reporter thus 
negating the need for an extra fluorophore labeling step.  For example, we are 
pursuing the incorporation of electroactive amino acids, such as 
benzoylphenylalanine in an effort to yield a protein which would elicit an 
electrochemical response upon glucose binding.  The palette of unnatural amino 
acids which can be incorporated during in vivo expression is somewhat limited 
based on the availability of auxotrophic strains and orthogonal tRNA/synthetase 
pairs.  Part of the motivation for truncating the proteins in the development of our 
sensing systems is the elucidation of minimized protein structures and 
identification of essential sequences necessary for protein function.  The 
identification of shorter amino acid sequence capable of functioning as a sensor 
for a desired analyte will allow for the possibility of solid phase peptide synthesis 
which greatly increases the variety of unnatural amino acids which can be 
employed. 
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 A final near-term pursuit of these biosensing systems will entail the 
incorporation into devices.  Some work in this direction has been pursued by our 
laboratory with the incorporation of protein based biosensors for glucose into 
fiber-optic based devices.  Preliminary work has been accomplished that 
demonstrates the proteins can be incorporated and maintain their binding and 
sensing activities.  Future pursuits should include detailed characterization of 
these devices with regards to their analytical properties such as sensitivity, 
selectivity, reproducibility, and lifetime.  Also, validation of the response of the 
device with real samples will need to be performed.  In addition, physical 
characteristics such as device storage, ruggedness, and transport will need to be 
studied.  Finally, the effects and mitigation of an immune response to an 
implanted fiber optic sensor will need to be investigated. 
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